

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The comparison of very early rule-out strategies for non-ST elevation myocardial infarction in emergency departments: protocol for a multicenter prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026985
Article Type:	Protocol
Date Submitted by the Author:	30-Sep-2018
Complete List of Authors:	<p>Tada, Masafumi; Kyoto University, Graduate School of Medicine and School of Public Health Azuma, Hiroyuki; Fukui Prefectural Hospital, Department of Emergency Medicine Yamada, Naoki; Fukui University Hospital, Department of Emergency Medicine Kano, Ken-ichi; Fukui Prefectural Hospital, Department of Emergency Medicine Nagai, Hideya; Fukui Prefectural Hospital, Department of Emergency Medicine Maeda, Shigenobu; Fukui Prefectural Hospital, Department of Emergency Medicine Ishida, Hiroshi; Fukui Prefectural Hospital, Department of Emergency Medicine Aoyama, Takahiko; Fukui Prefectural Hospital, Cardiology, Vascular Center Okada, Ryota; Fukui University Hospital, Department of Emergency Medicine Kawano, Takahisa; Fukui University Hospital, Department of Emergency Medicine Kobuchi, Taketsune; Fukui University Hospital, Department of Emergency Medicine Uzui, Hiroyasu; Fukui University Hospital, Department of Cardiovascular Medicine Matano, Hideyuki; Fukui-ken Saiseikai Hospital, Department of Emergency Medicine Iwasaki, Hose; Fukui-ken Saiseikai Hospital, Department of Emergency Medicine Maeno, Koji; Fukui-ken Saiseikai Hospital, Department of Cardiology Shimada, Yoshimitsu; Japanese Red Cross Fukui Hospital, Department of Emergency Medicine Yoshida, Hiroyuki; Japanese Red Cross Fukui Hospital, Department of Cardiology Ando, Masaki; Nagoya City East Medical Center, Department of Emergency Medicine Murakami, Yoshimasa; Nagoya City East Medical Center, Department of Cardiovascular Medicine Iwakami, Naotsugu; National Cerebral and Cardiovascular Center, Department of Research Promotion and Management Kishimoto, Sanae; Kyoto University, Graduate School of Medicine and School of Public Health</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Iwami, Taku ; Kyoto University , Department of Health Service Tada, Hiroshi; Fukui University Hospital, Department of Cardiovascular Medicine Chapman, Andrew; University of Edinburgh, British Heart Foundation Center for Cardiovascular Science Mills, Nicholas; University of Edinburgh, British Heart Foundation Center for Cardiovascular Science Hayashi, Hiroyuki; Fukui University Hospital, Department of Emergency Medicine Furukawa, Toshi; Kyoto University, Graduate School of Medicine and School of Public Health Watanabe, Norio; Kyoto University, Graduate School of Medicine and School of Public Health
Keywords:	ACCIDENT & EMERGENCY MEDICINE, Myocardial infarction < CARDIOLOGY, Cardiology < INTERNAL MEDICINE

peer review only

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **The comparison of very early rule-out strategies for non-ST elevation myocardial**
7 **infarction in emergency departments: protocol for a multicenter prospective cohort**
8 **study**
9
10
11
12
13

14 Masafumi Tada,¹ Yoshida-konoecho, Sakyo-ku, Kyoto 606-8501 Japan

15
16 Correspondence to: tada.masafumi.76r@st.kyoto-u.ac.jp. Phone: +81-75-753-9491
17
18
19

20 Hiroyuki Azuma,² Naoki Yamada,⁴ Ken-ichi Kano,² Hideya Nagai,² Shigenobu Maeda,²
21 Hiroshi Ishida,² Takahiko Aoyama,³ Ryota Okada,⁴ Takahisa Kawano,⁴ Taketsune
22 Kobuchi,⁴ Hiroyasu Uzui,⁵ Hideyuki Matano,⁶ Hose Iwasaki,⁶ Koji Maeno,⁷ Yoshimitsu
23 Shimada,⁸ Hiroyuki Yoshida,⁹ Masaki Ando,¹⁰ Yoshimasa Murakami,¹¹ Naotsugu
24 Iwakami,¹² Sanae Kishimoto,¹ Taku Iwami,¹³ Hiroshi Tada,⁵ Andrew R. Chapman,¹⁴
25 Nicholas L. Mills,¹⁴ Hiroyuki Hayashi,⁴ Toshiaki Furukawa,¹ Norio Watanabe¹
26
27
28
29
30
31
32
33

34 **Author affiliations**

35
36 ¹ Department of Health Promotion and Human Behavior, Kyoto University Graduate
37 School of Medicine, Yoshida-konoecho, Sakyo-ku, Kyoto 606-8501, Japan
38

39
40 ² Department of Emergency Medicine, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui
41 910-8526, Japan
42

43
44 ³ Cardiology, Vascular Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui 910-8526,
45 Japan
46

47
48 ⁴ Department of Emergency Medicine, Fukui University Hospital, 23-3
49 Matsuokashimoaizuki, Eihei-cho, Yoshida-gun, Fukui 910-1193, Japan
50

51
52 ⁵ Department of Cardiovascular Medicine, Fukui University Hospital, 23-3
53 Matsuokashimoaizuki, Eihei-cho, Yoshida-gun, Fukui 910-1193, Japan
54
55
56
57
58
59

1
2
3
4
5
6 ⁶ Department of Emergency Medicine, Fukui-ken Saiseikai Hospital, 7-1 Funabashi,
7
8 Wadanaka-cho, Fukui 918-8503, Japan
9

10 ⁷ Department of Cardiology, Fukui-ken Saiseikai Hospital, 7-1 Funabashi, Wadanaka-cho,
11
12 Fukui 918-8503, Japan
13

14 ⁸ Department of Emergency Medicine, Japanese Red Cross Fukui Hospital, 2-4-1 Tsukimi,
15
16 Fukui 918-8501, Japan
17

18 ⁹ Department of Cardiology, Japanese Red Cross Fukui Hospital, 2-4-1 Tsukimi, Fukui
19
20 918-8501, Japan
21

22 ¹⁰ Department of Emergency Medicine, Nagoya East Medical Center, 1-2-23 Wakamizu,
23
24 Chikusa-ku, Nagoya 464-8547, Japan
25

26 ¹¹ Department of Cardiovascular Medicine, Nagoya East Medical Center, 1-2-23 Wakamizu,
27
28 Chikusa-ku, Nagoya 464-8547, Japan
29

30 ¹² Department of Research Promotion and Management, National Cerebral and
31
32 Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan
33

34 ¹³ Department of Health Services, Kyoto University, Yoshida-Honmachi, Sakyo-ku, Kyoto,
35
36 606-8501, Japan
37

38 ¹⁴ British Heart Foundation Center for Cardiovascular Science, University of Edinburgh,
39
40 SU305 Chancellors Building, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, United
41
42 Kingdom
43

44 **Word count:** 3910

45
46 **Keywords:** myocardial infarction, high sensitivity troponin, clinical impression, prediction
47
48 rule
49

ABSTRACT

Introduction

Recent advances in troponin sensitivity enabled early and accurate judgement of ruling-out myocardial infarction, especially non-ST elevation myocardial infarction (NSTEMI) in emergency departments (ED) with development of various prediction-rules and high-sensitive-troponin-based strategies (hs-troponin). Reliance on clinical impression, however, is still common, and it remains unknown which of these strategies is superior. Therefore, our objective in this study is to validate and compare the diagnostic accuracy of clinical impression-based strategy, prediction-rules, and hs-troponin-based strategies for ruling-out NSTEMIs.

Methods and analysis

In total, 1500 consecutive adult patients with symptoms suggestive of acute coronary syndrome will be prospectively recruited from five EDs in two tertiary-, two secondary-level community hospitals, and one university hospital in Japan. The study has begun in July 2018, and recruitment period will be about one year. A board-certified emergency physician will complete standardized case report forms, and independently perform a clinical impression-based risk estimation of NSTEMI. Index strategies to be compared will include: the clinical impression-based strategy; prediction rules; and hs-troponin-based strategies for the following types of troponin (Roche Elecsys hs-troponin T; Abbott ARCHITECT hs-troponin I; Siemens ADVIA Centaur hs-troponin I; Siemens ADVIA Centaur sensitive-troponin I). The reference standard will be the composite of type 1 MI and cardiac death within 30 days after admission to the ED. Outcome measures will be NPV, sensitivity and effectiveness, defined as the proportion of patients categorized as low risk for NSTEMI. We will also evaluate inter-rater reliability of the clinical impression-based risk estimation.

Ethics and dissemination

The study is approved by the Ethics Committees of the Kyoto University Graduate School and Faculty of Medicine and of the five hospitals where we will recruit patients.

ARTICLE SUMMARY

Strengths and limitations of this study

- This is the first prospective study to compare clinical impression-based strategies, prediction-rules and hs-troponin-based strategies for ruling-out NSTEMI in patients with symptoms suggestive of acute coronary syndrome in ED.
- We also evaluate the inter-rater reliability of the clinical impression-based risk estimation and discuss the usefulness of the strategies considering both the diagnostic accuracy and the inter-rater reliability.
- We will use three high-sensitive-troponin and one sensitive-troponin which are currently widely available in order to increase the applicability of the results of our study.
- A limitation of the study is that troponin will rarely be taken later than three hours after presentation to ED and therefore, we may miss some MIs.

INTRODUCTION

Background

Because ruling-out non-ST elevation myocardial infarctions (NSTEMI) is often challenging, the American College of Cardiology (ACC) / American Heart Association (AHA) and European Society of Cardiology (ESC) 2007 guidelines mandate the serial troponin tests over a period of 6 to 12 h after symptom onset or admission to the emergency department (ED).(1, 2) This long period of observation is the principal reason for admitting patients with symptoms that might be related to an myocardial infarction (MI) and is, in fact, the most frequent reason for admission in ED in both the United Kingdom and the United States.(3, 4) However, in about 80 to 90% of patients presenting to EDs for a possible MI, the presenting symptoms are not cardiac in origin. Therefore, earlier and safer strategies to rule-out an MI in EDs, which would allow patients to be discharged directly from the ED, have been in a great demand. It is generally accepted that the risk of MI and death within 30 days should be less than one to two percent to patients directly discharged from the ED. (5, 6)

Recently, several high-sensitive-troponins (hs-troponin) have decreased the recommended time for troponin monitoring for MI diagnosis to 3-6 h (2014 ACC/AHA guidelines (7)), and further to 0-3 h (2015 ESC guidelines (8)). Furthermore, a large individual patient-level data meta-analysis reported that when the initial troponin value was much lower than the 99th percentile, the negative predictive value (NPV) was consistently >99% across the included cohorts.(9) Therefore, the time frame of serial troponin monitoring could be greatly shortened, or even made unnecessary, for certain populations. The population in East Asia may be appropriate for very early 'ruling-out' strategies of MI since the incidence of MI in East Asia, especially in Japan, is much lower than in Western countries.(10)

1
2
3
4
5
6 Although troponin is crucial for the acute management of MI, history, physical findings and
7 electronic cardiogram (ECG) are also essential. Several clinical decision-making models
8 have been developed for MI, including the clinical impression-based strategy, prediction
9 rules and the hs-troponin-based strategy. The clinical impression-based strategy is a
10 traditional approach consisting of the clinical impression-based risk estimation of history and
11 physical findings, ECG and troponin. However, the inter-rater reliability of the risk
12 estimation for MI based on clinical impression has not been comprehensively evaluated, and
13 previous studies suggested that risk estimation for MI, based on clinical impression, might
14 vary greatly, depending on a physician's background.(11, 12)
15
16
17
18
19
20
21
22
23
24
25

26 Prediction rules have been developed that consider clinical findings and troponin monitoring
27 in a structured way to determine the risk of an MI. Several prediction rules to estimate the
28 risk of an MI have been defined, including the TIMI,(13) HEART,(14) EDACS,(15) and
29 T-MACS(16) rules. Most of the newer prediction rules that have incorporated hs-troponin
30 have achieved an NPV of >99% and have been validated.(17-20) Prediction rules, however,
31 are not widely used, despite their excellent NPVs, partly because they have not been
32 compared against clinical impression-based strategies.(21)
33
34
35
36
37
38
39
40
41

42 There are several hs-troponin-based strategies that use only hs-troponin, such as the 0 and 1h
43 algorithm,(22) the 0 and 2h algorithm(23) and the High-STEACS pathway.(24) These
44 strategies are simple, and they rely on a measurement of troponin only, with demonstrated
45 NPVs of >99%. However, clinicians consider patient history and physical findings
46 (including the ECG) as being essential components of the evaluation of a patient's status,
47 with no clear pathway to include these in hs-troponin-based strategies. Moreover, the cutoffs
48 of troponin levels in these hs-troponin strategies tend to be much lower than the 99th
49
50
51
52
53
54
55
56
57
58
59
60

percentile and patient age, which has previously been associated with an increase in troponin level,(25, 26) has not been considered. As such, hs-troponin-based strategies may be less efficient in highly aged populations, such as in Japan.

Rationale for the study

First, a direct comparison of the clinical impression-based strategies, prediction-rules and hs-troponin-based strategies to rule out NSTEMI has not yet been published and, therefore, there is a need for a well-designed study to compare their accuracy.

Second, although the use of serial troponin and the cutoffs below the 99th percentile of troponin are recommended in Western countries, it has not yet been proven well in East Asia, where the incidence of MI is low and reliance on the clinical impression-based strategy is common.(10) Because serial troponin is not only time consuming, but requires additional resources and medical expenses, there is a need, particularly in East Asia, to evaluate the NPV of clinical impression-based strategies, combined with troponin levels obtained at different time points, using the 99th percentile cutoff value.

Third, although many kinds of troponins are now available, the diagnostic accuracy and cutoff are each troponin specific. Our proposed study will include the four types of troponin that are currently widely available: Roche hs-troponin T; Abbott hs-troponin I; Siemens hs-troponin I; Siemens sensitive-troponin I in order to increase the applicability of our results to as many facilities as possible.

Study objectives

1. Primary research objective

Our primary objective is to compare the NPV, sensitivity and effectiveness (defined as the proportion of patients categorized into low risk to all patients to whom a strategy was applied) of the three clinical impression-based strategies with three time frames of troponin monitoring: on arrival (0 h) only; 0 h and 1 h after; and 0 h and 2 h after, using the composite outcome of cardiac death or the occurrence of a type 1 MI within 30 days of the ED consultation.

2. Secondary research objectives

Our secondary research objectives are:

- 2.1. To validate and compare the NPV, sensitivity and effectiveness between clinical impression-based strategies, prediction rules and hs-troponin-based strategies.
- 2.2. To evaluate the inter-rater reliability of the clinical impression-based strategy, in estimating the risk estimation of an MI, when performed by board certified emergency physicians and senior residents of emergency medicine, general internists, cardiologists, junior residents, and nurses.

METHODS AND ANALYSIS

Inclusion criteria

1. Age ≥ 25 years
2. Have any one of the following symptoms suspected to be MI
 - Chest pain
 - Non-chest pain, including radiating pain, syncope, dyspnea, nausea / vomiting, and fatigue, and other symptoms which emergency physicians judge to need to rule out an MI

3. Presentation to the ED within 6 hours from symptom onset. We will set the threshold at six hours to focus on early presenters, the most difficult population to rule-out NSTEMI very early (27)
4. No apparent ST elevation on arrival
5. The use of both ECG and the troponin test, as deemed to be required by the ED physician

Exclusion criteria

1. Cardiopulmonary arrest on arrival
2. Non-cardiac terminal illness (expected survival less than six months)
3. Need for resuscitation (physiological shock, continuous oxygen administration)
4. Indication of emergency catheterization on arrival
5. Inability of the patient to provide consent
6. Previous inclusion in the study
7. Unable to contact for follow-up after 30 days
8. Unknown time of onset of symptoms
9. Apparent need to admit for a diagnosis other than acute coronary syndrome on arrival
10. Patients on maintenance dialysis
11. Judged as ineligible by an emergency physician

Participants recruitment

When an MI is suspected, an ECG will be obtained first, as per usual practice. If there is no significant ST elevation, a board-certified emergency physician will assess the eligibility of the patient for enrollment into the study. Because board-certified emergency physicians are not regularly available at night or on weekends in three of the participating hospitals

(Fukui-ken Saiseikai hospital; Japanese Red Cross Fukui Hospital; and Nagoya East Medical Center), patients will only be recruited when board-certified emergency physicians are working in these centers. In the other two facilities (Fukui Prefectural Hospital and Fukui University Hospital), board-certified emergency physicians are available around the clock and, therefore, patients will be recruited as they present to the EDs.

Informed consent

We will obtain written informed consent from all patients. Because MI is more common in the elderly, it may be sometimes difficult to obtain informed consent from some patients due to dementia. Because excluding these patients will impair the validity of the study, we will seek to obtain consent from patient's authorized proxy in such cases. We will conduct this study in accordance with the Declaration of Helsinki and its amendments. This study is registered in the UMIN-CTR registry (UMIN 000029992).

Clinical assessments

The following assessments will be performed at each site using standardized case report forms (CRF): history; physical examination; clinical impression-based risk estimation; ECG; standard blood tests; ultrasonography; and troponin levels (using both in-house and research troponin types). Clinical impression-based risk estimation for a NSTEMI will be classified as low, intermediate or high for analysis. The certainty of each item of the clinical history and ECG will be measured using a 4-point Likert scale. The inter-rater reliability will be evaluated between a board-certified emergency physician and one of the following medical staff: a board-certified emergency physician; an emergency medicine resident; a junior resident; a general practitioner; a cardiologist; or a nurse for 300 consecutive patients enrolled into the study. The following variables will be included for

inter-rater reliability: clinical impression-based risk estimation; each item of the clinical history; ECG; ultrasonography. Assessors will not be provided with results of the troponin levels, ultrasonography examination or the previous assessment performed by another emergency physician or cardiologist before completion of the CRF. Because it will occasionally be difficult to mask this information, we will report the masking status. Management of patients will be left to the discretion of treating emergency physicians and cardiologists, based on the results of in-house troponin measurements in each hospital. The indication of early invasive strategy will follow current guidelines. (7, 8, 28)

Troponin

We will evaluate the following four types of troponin, three high-sensitive and one sensitive. The 99th percentile and the Limit of detection (LoD) values for the four types of troponin are summarized in Table 1. We will use sex-specific 99th percentile values for three types of hs-troponin in sensitivity analyses. We will collect blood samples in serum tubes for troponin levels on arrival (0 h); and at one hour (1 h), two hours (2 h), and three hours (3 h) after the first blood draw. After centrifugation, serum samples will be stored at less than -20°C until measured in each manufacturer's laboratory in a blinded fashion.

Table 1 The 99th percentile and LoD values for four types of troponin

Troponin	99 th percentile (ng/L)	LoD (ng/L)
Roche Elecsys hs-troponin T (general)	14.0	3.0
Roche Elecsys hs-troponin T (male)	15.5	
Roche Elecsys hs-troponin I (female)	9.0	
Abbott ARCHITECT hs-troponin I (general)	26.2	1.9

Abbott ARCHITECT hs-troponin I (male)	34.2	
Abbott ARCHITECT hs-troponin I (female)	15.6	
Siemens ADVIA Centaur hs-troponin I (general)	46.5	2.2
Siemens ADVIA Centaur hs-troponin I (male)	58.1	
Siemens ADVIA Centaur hs-troponin I (female)	39.6	
Siemens ADVIA Centaur sensitive-troponin I	40.0	6.0

LoD indicates limit of detection

Index tests

We will evaluate the three types of decision-making models to rule-out MI: the clinical impression-based strategies, prediction rules, and hs-troponin-based strategies. An author (MT) searched PubMed (December 2017) for prediction rules and hs-based strategies to rule-out MI in ED. We also consulted reviews on this topic to identify suitable decision-making models. Among identified prediction-rules and hs-troponin-based strategies, we selected those which were validated and showed an NPV of >99%, using any types of troponin. Each troponin will be adapted for each strategy, as needed. We will define the troponin cutoff at the 99th percentile value, except for hs-troponin-based strategies, and the T-MACS. The troponin cutoffs for hs-troponin-based strategies are specific for each type of troponin, as detailed below. Troponin values will be incorporated as a continuous variable in the T-MACS. We will adopt cutoffs for each strategy in accordance with the original publication for each strategy.

The clinical impression-based strategies

1. The 0 h model

- 1
- 2
- 3
- 4
- 5
- 6 1) Clinical impression-based risk estimation for history and physical findings is not high
- 7 risk
- 8
- 9
- 10 2) No new ischemic findings on ECG
- 11
- 12 3) Troponin taken on arrival is below the 99th percentile
- 13
- 14
- 15

16 2. The 0 h and 1 h model

- 17
- 18 1) Clinical impression-based risk estimation for history and physical findings is not high
- 19 risk
- 20
- 21
- 22 2) No new ischemic findings on ECG
- 23
- 24 3) Troponin taken on arrival and at 1 h apart are both below the 99th percentile
- 25
- 26
- 27

28 3. The 0 h and 2 h model

- 29
- 30 1) Clinical impression-based risk estimation for history and physical findings is not high
- 31 risk
- 32
- 33
- 34 2) No new ischemic findings on ECG
- 35
- 36 3) Troponin taken on arrival and at 2 h apart are both below the 99th percentile
- 37
- 38
- 39

40 We will evaluate the clinical impression-based risk estimation for history and physical
41 findings based on the AHA/ACC guideline(29) and a systematic review.(30) We define the
42 new ischemic findings on ECG as an ST depression and negative T wave not known to be
43 old. An ST depression is defined by a depression of 0.05mV or more at J point in two or
44 more contiguous leads. A negative T wave is defined by T wave inversions of 0.1mV or
45 more in two or more contiguous leads. If all three components of each model are satisfied,
46 we regard a patient as being at low risk for an MI.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Prediction rules

1. TIMI + 2 h troponin(31)

Components: age, coronary risk factors, use of aspirin, significant coronary stenosis, severe angina, ECG, and troponin (at 0 and 2 h)

Cutoff: we will define the score of 0 as a low risk for MI

2. HEART(14)

Components: history, ECG, age, risk factors, and troponin

Cutoff: we will define the score of 0-3 and negative troponin as a low risk for MI

3. EDACS(15)

Components: age, sex, coronary artery disease or risk factors, symptoms, ECG, and troponin (at 0 and 2 h)

Cutoff: we will define low risk when all three conditions are satisfied, namely: a score < 16; no new ischemia on ECG; and negative troponin at 0 and 2 h

4. T-MACS(16)

Components: (a) hs-troponin T (at 0 h), (b) ECG, (c) objective sweating, (d) vomiting, (e) systolic blood pressure <100 mmHg on arrival, (f) worsening angina, and (g) pain radiating to the right arm or shoulder

probability = $1 / (1 + e^{-(0.068a + (0.17(b - 0.28) / 1.35) + 1.75c + 1.85d + 1.72e + 1.46f + 0.92g + 0.87h - 4.83)})$

Cutoff: we will define low risk if the probability is <0.02

5. TRUST(32)

Components: typical new-onset chest pain at rest, pain the same as previous MI, pain not relieved by glyceryl trinitrate within 15 min, pain lasting more than 60 min, pain occurring with increasing frequency, hypotension, acute shortness of breath, pain within 6 weeks of an MI or revascularization, ECG, hs-troponin (at 0 h)

Cutoff: we will define low risk when all three conditions are satisfied: the score of 0 or 1, non-ischemic ECG, and negative troponin

Hs-troponin-based strategies

Hs-troponin-based strategies are comprised of hs-troponin only, with cutoff values being troponin specific, as shown below for the five algorithms that will be used in the study. If a troponin value is below the cutoff values of each strategy, we regard a patient as being at low risk for an MI.

1. The 0 h algorithm(33, 34)

Roche hs-troponin T: 0 h <5 ng/L^(*1)

Abbott hs-troponin I: 0 h <2 ng/L^(*2)

Siemens hs-troponin I: 0 h <3 ng/L^(*3)

Siemens sensitive-troponin I: 0 h <0.5 ng/L^(*4)

2. The 1 h algorithm(22, 34-36)

Roche hs-troponin T: 0 h <12 ng/L AND Δ 0-1 h <3 ng/L^(*5)

Abbott hs-troponin I: 0 h <5 ng/L AND Δ 0-1 h <2 ng/L^(*6)

Siemens hs-troponin I: 0 h <6 ng/L AND Δ 0-1 h <3 ng/L^(*7)

Siemens sensitive-troponin I: 0 h <10 ng/L AND Δ 0-1 h <4 ng/L^(*8)

3. The 2 h algorithm(23, 36, 37)

Roche hs-troponin T: 0 and 2 h <14 ng/L AND Δ 0-2 h <4 ng/L

Abbott hs-troponin I: 0 and 2 h <6 ng/L AND Δ 0-2 h <2 ng/L

Siemens sensitive-troponin I: 0 and 2 h <10 ng/L

1
2
3
4
5
6
7
8 4. The 0 and 1h algorithm(8, 34)
9

10 Roche hs-troponin T: *1 OR *5

11 Abbott hs-troponin I: *2 OR *6

12 Siemens hs-troponin I: *3 OR *7

13 Siemens sensitive-troponin I: *4 OR *8
14
15
16
17
18
19

20 5. The High-STEACS pathway (only for Abbott hs-troponin I at the moment) (24)
21

22 If hs-troponin I at 0 h <5 ng/L AND symptom onset ≥ 2 h, AMI is ruled out.

23 If $5 \leq$ hs-troponin I at 0 h ≤ 26.2 ng/L OR symptom onset < 2 h, hs-troponin I at 2 h is
24 required. If $\Delta 0-2$ h hs-troponin I < 3 ng/L AND hs-troponin I at 3 h ≤ 26.2 ng/L, AMI is
25 ruled out.
26
27
28
29
30
31

32 **Reference standard**
33

34 **Final diagnosis adjudication**
35

36 Two cardiologists of each facility will independently adjudicate the final diagnosis based
37 on the results of the follow-up telephone interview and all available clinical information
38 obtained 30 days or more after the admission to the ED: each item of the clinical history;
39 physical examination; laboratory tests (both in-house troponin and hs-troponin T taken at 0
40 and 3 h); ECG; ultrasonography; cardiac stress test; radiological test; and coronary
41 angiography. Disagreements will be resolved through discussions between the two
42 cardiologists. If they are unable to reach consensus, a third cardiologist will be consulted.
43
44 All cardiologists will be masked from the results of index tests and the research hs-troponin
45 obtained at 1 and 2 h.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 The diagnosis of MI will be made in accordance with the forth universal definition of
7 myocardial infarction,(38) and classified as type 1, type 2, type 4b, and myocardial injury.
8 Briefly, an MI will be diagnosed if there is a significant rise and/or fall of troponin, with at
9 least one value above the 99th percentile, in a clinical setting consistent with acute
10 myocardial ischemia. We will use Radiometer AQT90 FLEX Troponin T and Abbott
11 ARCHITECT hs-troponin I to adjudicate the final diagnosis in three facilities which using
12 Radiometer AQT90 FLEX Troponin T as in-house troponin. Because Radiometer troponin
13 T is less sensitive than Abbott ARCHITECT hs-troponin I and therefore, we generally
14 prioritize the result of hs-troponin I if the results of the two types troponin are
15 discordant.(27, 39) We also consider clinical judgement and all available clinical
16 information to interpret the discordant cases. We will use Abbott ARCHITECT hs-troponin
17 I to adjudicate the final diagnosis in two facilities which using Abbott ARCHITECT
18 hs-troponin I as in-house troponin. The 99th percentile values for Abbott hs-troponin I has
19 previously been defined. The 99th percentile values for Radiometer AQT90 FLEX Troponin
20 T will be 17 ng/L. For Abbott hs-troponin I and Radiometer AQT90 FLEX Troponin T, we
21 will define a significant rise and/or fall as relative increase of >50% of the respective 99th
22 percentile value if the initial troponin value is equal or less than the 99th percentile value,
23 and as relative increase of >20% of the initial value if the initial troponin values is greater
24 than the 99th percentile value.(40) Type 1 MI is defined as myocardial necrosis with
25 symptoms suggestive of MI or test results which prove myocardial ischemia. Type 2 MI is
26 defined as myocardial necrosis, with a condition other than coronary artery disease, which
27 contributes to an oxygen supply-demand imbalance (e.g. coronary artery spasm;
28 tachyarrhythmia; respiratory failure; or anemia). Type 4b is an MI associated with stent
29 thrombosis.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Clinical outcomes

The primary clinical outcome will be the composite of type 1 MI and cardiac death within 30 days of the ED admission. If patients consult an ED or cardiac service in the study facility again, emergency physicians or cardiologists will ask patients if they have had an MI or if they have undergone any cardiac tests or revascularization in other hospitals. Because not all patients can be expected to consult a study facility again, research staffs will conduct structured telephone follow-up interview with all patients enrolled into the study, 30 days after the ED admission. At 30 days, if patients have either consulted a study facility again or if sufficient clinical information is available, we will include only type 1 MI as the primary clinical outcome. Whilst for patients who do not consult a study facility again and, therefore, only information from the telephone follow-up is for clinical outcomes, it will be difficult to differentiate type 1 MI from other types of MI. In these cases, we will include all MI types (1, 2 and 4b) as the primary clinical outcome. Similarly, the adjudication of a cause of death might be difficult in some patients. In this case, we will include an unknown cause of death into our primary outcome. Patients who do not consult a study facility again and could not be reached for the telephone follow-up interview will be excluded from the primary and secondary research objectives. We will conduct a sensitivity analysis to determine the effect of missing patients on our findings, using the worst case scenario.

Sample size calculation

Assuming that the event rate of the primary clinical outcome is 5 to 10%, (9, 10) with a sensitivity and specificity of the clinical impression-based strategies of 95% and 55%, respectively, (41) 1500 patients will need to be enrolled into the study if the lower limit of 95% CI of the NPV is to surpass 98%.

Data analysis

Primary research objective

We will describe the NPV, sensitivity and effectiveness of the three clinical impression-based strategies, using the 95%CI for each troponin. We will also calculate the specificity, positive predictive value, area under the receiver operating characteristic curve (AUC), and decision curve analysis (DCA) for each strategy. Although we will compare the NPV, sensitivity, effectiveness and AUC among the three strategies, we will regard a strategy as being clinically useful if the point estimate for NPV is $\geq 99\%$. If the point estimate for NPV is $\geq 99\%$, we will regard a strategy with shorter observational period as superior.

Secondary research objective 1

We will describe the NPV, sensitivity, effectiveness, AUC and DCA for the clinical impression-based strategies, prediction rules, and hs-troponin-based strategies for each troponin. If the point estimate for NPV is $\geq 99\%$, we will regard a strategy with higher effectiveness and shorter observational period as superior.

Secondary research objective 2

Reliability will be evaluated for 300 consecutive patients. We will use Cohen's weighted Kappa-statistic and the boot-strap method, with 1000 replications, to determine the 95% CI boundaries of reliability.

Sensitivity analysis

1
2
3
4
5
6 A sensitivity analysis will be performed including type 2 and 4b MI to the primary clinical
7 outcome. We will compare the NPV, sensitivity and effectiveness of the index tests
8 between subgroups stratified by: time from symptom onset to hospital arrival; the clinical
9 impression-based risk estimation; past history of ischemic heart disease or
10 revascularization; age; sex; and presence of chest pain considering its certainty. We will
11 define the cutoff of the clinical impression-based risk estimation as neither moderate nor
12 high. We also perform analyses by changing the cutoffs of other strategies. We will
13 combine the hs-troponin-based strategies with clinical impression-based risk estimation
14 and/or ECG, and evaluate the NPV, sensitivity, and effectiveness. We will use each of
15 Roche Elecsys hs-troponin T; Siemens ADVIA Centaur hs-troponin I; Siemens ADVIA
16 Centaur sensitive-troponin I for the adjudication of MI. We will use sex-specific 99th
17 percentiles of three types of hs-troponin for the index tests. We will determine the effect of
18 missing patients on our findings, using the worst case scenario.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Ethics and dissemination**

35
36 This study is approved by the Ethics Committees of the Kyoto University Graduate School
37 and Faculty of Medicine (R1380, 27 February 2018) and the five hospitals where we will
38 recruit patients. We will disseminate results of the study through peer-reviewed journals
39 and conference presentations.
40
41
42
43
44
45

46 **Summary**

47
48 Along with the advance in troponin monitoring, the early management of MI suspected
49 patients is markedly changing. Though many troponins are available now, diagnostic
50 accuracy and cutoff values are specific for each type of troponin. Although many
51 prediction-rules and hs-troponin-based strategies have been published, it is still unknown if
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 these algorithms are superior to clinical impression-based strategies. The study will be the
7
8 first prospective study to compare clinical impression-based strategies, using four different
9
10 types of troponin which is commonly used, to estimate the risk of an MI with prediction-rules
11
12 and hs-troponin-based strategies. We will also evaluate the inter-rater reliability of the
13
14 clinical impression-based risk estimation, and discuss the usefulness of these strategies,
15
16 considering both the diagnostic accuracy and the inter-rater reliability.
17
18
19

20 **Acknowledgments**

21
22 The authors sincerely thank the patients who are participating in the study. The authors
23
24 warmly thank emergency physicians, S. Tanizaki, M. Sera, M. Hayashi, T. Nakanishi, H.
25
26 Watanabe, and J. Tanaka in Fukui prefectural hospital; T. Kimura, H. Morita, T. Yamanaka,
27
28 T. Hamada, H. Tsuji, Y. Kuwabara, Y. Kamikawa in Fukui university hospital; M. Inagaki, T.
29
30 Miura, T. Ohno in Nagoya east medical center. The authors would like to thank cardiologists,
31
32 S. Fujino, M. Yamaguchi, Y. Noji, H. Kato, R. Yamamura, N. Ukawa, Y. Takahashi in Fukui
33
34 prefectural hospital; S. Miyazaki, K. Ishida, K. Kaseno, K. Hasegawa, T. Morishita, Y.
35
36 Fukuoka, H. Ikeda, N. Tama, Y. Shiomi, J. Yamaguchi, D. Aoyama, T. Aiki, E. Ishikawa, M.
37
38 Mukai, A. Matsui, K. Miyahara in Fukui university hospital; H. Takemori, K. Ohkura, M.
39
40 Hirazawa, S. Ohkura, H. Tsuneyama in Fukui-ken Saiseikai hospital; T. Akiyoshi, K.
41
42 Sarazawa, K. Sakakibara, J. Yamaguchi, T. Kataoka in Japanese red cross Fukui hospital; T.
43
44 Saeki, N. Tamai, S. Yamashita, T. Yoshida, T. Sekimoto, K. Hachiya, T. Hasuo, T.
45
46 Hashimoto, T. Noda in Nagoya east medical center.
47

48 The authors also thank general physicians, residents, nurses, and clinical technologists of the
49
50 five study hospitals for their voluntary co-operation. The authors acknowledge clinical
51
52 laboratory technologists of the five study hospitals for blood sample handling; and the Roche
53
54 and T. Kikuchi, the Abbott and S. Sugawa, and the Siemens and T. Yokoyama for biomarker
55
56
57
58
59

1
2
3
4
5
6 measurement including troponin. The authors also appreciate K. Yamamoto and the Union
7
8 Think for offering an optical character recognition program to incorporate data of paper CRF
9
10 into REDCap (version 8.1.17; Nashville, TN) electronic data capturing system.
11
12

13 14 **Author contributions**

15
16 MT, NW wrote the first draft. All other authors, HA, NY, KK, HN, SM, HI, TA, RO, TK, TK,
17
18 HU, HT, HM, HI, KM, YS, HY, MA, YM, NI, SK, TI, HT, AC, NM, HH and TF contributed
19
20 to the conception and design of the study. All the authors read and approved the final
21
22 manuscript.
23
24

25 26 **Funding**

27
28 The study is supported by grants from Nakatani Foundation (Tokyo, Japan), and from
29
30 Radiometer (Tokyo, Japan).
31
32

33 34 **Competing interests**

35
36 MT received non-financial support from Roche, Abbott, and Siemens during the conduct of
37
38 the study; personal fees from Japan Medical Journal, outside the submitted work. ARC has
39
40 received honoraria from Abbott Diagnostics and AstraZeneca. NLM has received honoraria
41
42 and consultancy from Abbott Diagnostics, Roche Diagnostics and Singulex. TF reports
43
44 personal fees from Meiji Seika, grants and personal fees from MSD, personal fees from
45
46 Pfizer, outside the submitted work. NW has received research funds from the Japanese
47
48 Ministry of Health Labor and Welfare, the Japanese Ministry of Education, Science, and
49
50 Technology and National Center of Neurology and Psychiatry, Intramural Research Grant
51
52 for Neurological and Psychiatric Disorders. He has also received royalties from Sogensha
53
54 and Akatsuki. All other authors report no conflicts.
55
56
57
58
59
60

REFERENCES

1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *Circulation*. 2007;116(7):e148-304.
2. Task Force for D, Treatment of Non STSEACSoESoC, Bassand JP, Hamm CW, Ardissino D, Boersma E, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. *European heart journal*. 2007;28(13):1598-660.
3. Niska R, Bhuiya F, Xu J. National Hospital Ambulatory Medical Care Survey: 2007 emergency department summary. *Natl Health Stat Report*. 2010(26):1-31.
4. The Health and Social Care Information Centre. Hospital Episode Statistics, Admitted Patient Care-England, 2012-13: Primary diagnosis, 3 characters table.
5. Miller C. Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome. *Up To Date*. 2016.
6. Mahler SA, Miller CD, Hollander JE, Nagurney JT, Birkhahn R, Singer AJ, et al. Identifying patients for early discharge: performance of decision rules among patients with acute chest pain. *International journal of cardiology*. 2013;168(2):795-802.
7. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Jr., Ganiats TG, Holmes

1
2
3
4
5
6 DR, Jr., et al. 2014 AHA/ACC guideline for the management of patients with
7 non-ST-elevation acute coronary syndromes: a report of the American College
8 of Cardiology/American Heart Association Task Force on Practice Guidelines.
9 *Circulation*. 2014;130(25):e344-426.

10
11
12 8. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F,
13 et al. 2015 ESC Guidelines for the management of acute coronary syndromes in
14 patients presenting without persistent ST-segment elevation: Task Force for
15 the Management of Acute Coronary Syndromes in Patients Presenting without
16 Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
17 *European heart journal*. 2016;37(3):267-315.

18
19 9. Chapman AR, Lee KK, McAllister DA, Cullen L, Greenslade JH, Parsonage
20 W, et al. Association of High-Sensitivity Cardiac Troponin I Concentration
21 With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. *Jama*.
22 2017;318(19):1913-24.

23
24 10. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al.
25 Cardiovascular disease and risk factors in Asia: a selected review.
26 *Circulation*. 2008;118(25):2702-9.

27
28 11. Hess EP, Brison RJ, Perry JJ, Calder LA, Thiruganasambandamoorthy V,
29 Agarwal D, et al. Development of a clinical prediction rule for 30-day cardiac
30 events in emergency department patients with chest pain and possible acute
31 coronary syndrome. *Annals of emergency medicine*. 2012;59(2):115-25 e1.

32
33 12. Wu WK, Yiadom MY, Collins SP, Self WH, Monahan K. Documentation of
34 HEART score discordance between emergency physician and cardiologist
35 evaluations of ED patients with chest pain. *The American journal of emergency*
36 *medicine*. 2017;35(1):132-5.

37
38 13. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et
39 al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for
40 prognostication and therapeutic decision making. *Jama*. 2000;284(7):835-42.

41
42 14. Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value
43 of the HEART score. *Netherlands heart journal : monthly journal of the*
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Netherlands Society of Cardiology and the Netherlands Heart Foundation.

7 2008;16(6):191-6.

8
9 15. Than M, Flaws D, Sanders S, Doust J, Glasziou P, Kline J, et al.
10 Development and validation of the Emergency Department Assessment of Chest
11 pain Score and 2 h accelerated diagnostic protocol. *Emerg Med Australas*.
12 2014;26(1):34-44.

13
14
15 16. Body R, Carlton E, Sperrin M, Lewis PS, Burrows G, Carley S, et al.
16 Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid:
17 single biomarker re-derivation and external validation in three cohorts.
18 *Emergency medicine journal : EMJ*. 2017;34(6):349-56.

19
20
21 17. Cullen L, Mueller C, Parsonage WA, Wildi K, Greenslade JH, Twerenbold
22 R, et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic
23 strategy to assess 30-day outcomes in emergency department patients with
24 possible acute coronary syndrome. *Journal of the American College of*
25 *Cardiology*. 2013;62(14):1242-9.

26
27
28 18. Meller B, Cullen L, Parsonage WA, Greenslade JH, Aldous S, Reichlin
29 T, et al. Accelerated diagnostic protocol using high-sensitivity cardiac
30 troponin T in acute chest pain patients. *International journal of cardiology*.
31 2015;184:208-15.

32
33
34 19. McCord J, Cabrera R, Lindahl B, Giannitsis E, Evans K, Nowak R, et
35 al. Prognostic Utility of a Modified HEART Score in Chest Pain Patients in
36 the Emergency Department. *Circulation Cardiovascular quality and outcomes*.
37 2017;10(2).

38
39
40 20. Carlton EW, Khattab A, Greaves K. Identifying Patients Suitable for
41 Discharge After a Single-Presentation High-Sensitivity Troponin Result: A
42 Comparison of Five Established Risk Scores and Two High-Sensitivity Assays.
43 *Annals of emergency medicine*. 2015;66(6):635-45 e1.

44
45 21. Adams ST, Leveson SH. Clinical prediction rules. *Bmj*. 2012;344:d8312.

46
47 22. Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger
48 C, et al. One-hour rule-out and rule-in of acute myocardial infarction using
49
50
51
52
53
54
55
56
57
58
59
60

high-sensitivity cardiac troponin T. Archives of internal medicine.

2012;172(16):1211-8.

23. Reichlin T, Cullen L, Parsonage WA, Greenslade J, Twerenbold R, Moehring B, et al. Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Am J Med. 2015;128(4):369-79 e4.

24. Chapman AR, Anand A, Boeddinghaus J, Ferry AV, Sandeman D, Adamson PD, et al. Comparison of the Efficacy and Safety of Early Rule-Out Pathways for Acute Myocardial Infarction. Circulation. 2017;135(17):1586-96.

25. Riedlinger D, Mockel M, Muller C, Holert F, Searle J, von Recum J, et al. High-sensitivity cardiac troponin T for diagnosis of NSTEMI in the elderly emergency department patient: a clinical cohort study. Biomarkers. 2018;23(6):551-7.

26. Welsh P, Preiss D, Shah ASV, McAllister D, Briggs A, Boachie C, et al. Comparison Between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. Clinical chemistry. 2018.

27. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. The New England journal of medicine. 2009;361(9):858-67.

28. Kimura T. Guidelines for Management of Acute Coronary Syndrome without Persistent ST Segment Elevation (JCS 2012). 2012.

29. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of

1
2
3
4
5
6 Cardiovascular and Pulmonary Rehabilitation and the Society for Academic
7 Emergency Medicine. *Journal of the American College of Cardiology*.
8 2007;50(7):e1-e157.

9
10 30. Fanaroff AC, Rymer JA, Goldstein SA, Simel DL, Newby LK. Does This
11 Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical
12 Examination Systematic Review. *Jama*. 2015;314(18):1955-65.

13
14 31. Than M, Cullen L, Aldous S, Parsonage WA, Reid CM, Greenslade J, et
15 al. 2-Hour accelerated diagnostic protocol to assess patients with chest pain
16 symptoms using contemporary troponins as the only biomarker: the ADAPT trial.
17 *Journal of the American College of Cardiology*. 2012;59(23):2091-8.

18
19 32. Carlton EW, Cullen L, Than M, Gamble J, Khattab A, Greaves K. A novel
20 diagnostic protocol to identify patients suitable for discharge after a single
21 high-sensitivity troponin. *Heart*. 2015;101(13):1041-6.

22
23 33. Rubini Gimenez M, Hoeller R, Reichlin T, Zellweger C, Twerenbold R,
24 Reiter M, et al. Rapid rule out of acute myocardial infarction using
25 undetectable levels of high-sensitivity cardiac troponin. *International*
26 *journal of cardiology*. 2013;168(4):3896-901.

27
28 34. Boeddinghaus J, Twerenbold R, Nestelberger T, Badertscher P, Wildi
29 K, Puelacher C, et al. Clinical Validation of a Novel High-Sensitivity Cardiac
30 Troponin I Assay for Early Diagnosis of Acute Myocardial Infarction. *Clinical*
31 *chemistry*. 2018.

32
33 35. Rubini Gimenez M, Twerenbold R, Jaeger C, Schindler C, Puelacher C,
34 Wildi K, et al. One-hour rule-in and rule-out of acute myocardial infarction
35 using high-sensitivity cardiac troponin I. *Am J Med*. 2015;128(8):861-70 e4.

36
37 36. Druey S, Wildi K, Twerenbold R, Jaeger C, Reichlin T, Haaf P, et al.
38 Early rule-out and rule-in of myocardial infarction using sensitive cardiac
39 Troponin I. *International journal of cardiology*. 2015;195:163-70.

40
41 37. Boeddinghaus J, Reichlin T, Cullen L, Greenslade JH, Parsonage WA,
42 Hammett C, et al. Two-Hour Algorithm for Triage toward Rule-Out and Rule-In
43 of Acute Myocardial Infarction by Use of High-Sensitivity Cardiac Troponin
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 I. Clinical chemistry. 2016;62(3):494–504.

7 38. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et
8 al. Fourth universal definition of myocardial infarction (2018). European
9 heart journal. 2018.

10 39. Dupuy AM, Sebbane M, Roubille F, Coste T, Bargnoux AS, Badiou S, et
11 al. Analytical evaluation of point of care cTnT and clinical performances in
12 an unselected population as compared with central laboratory highly sensitive
13 cTnT. Clin Biochem. 2015;48(4–5):334–9.

14 40. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg
15 S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care.
16 European heart journal. 2012;33(18):2252–7.

17 41. Body R, Cook G, Burrows G, Carley S, Lewis PS. Can emergency physicians
18 'rule in' and 'rule out' acute myocardial infarction with clinical judgement?
19 Emergency medicine journal : EMJ. 2014;31(11):872–6.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



TRIPOD Checklist: Prediction Model Validation

Section/Topic	Item	Checklist Item	Page
Title and abstract			
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	3
Introduction			
Background and objectives	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	5-7
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	7-8
Methods			
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	1
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	3
Participants	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	3, 9-10
	5b	Describe eligibility criteria for participants.	8-9
	5c	Give details of treatments received, if relevant.	NA
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	16-18
	6b	Report any actions to blind assessment of the outcome to be predicted.	16
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	10-12
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	11
Sample size	8	Explain how the study size was arrived at.	18
Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	18, 20
Statistical analysis methods	10c	For validation, describe how the predictions were calculated.	12-16
	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	18-19
	10e	Describe any model updating (e.g., recalibration) arising from the validation, if done.	NA
Risk groups	11	Provide details on how risk groups were created, if done.	NA
Development vs. validation	12	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	NA
Results			
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	
	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	
	13c	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	
Model performance	16	Report performance measures (with CIs) for the prediction model.	
Model-updating	17	If done, report the results from any model updating (i.e., model specification, model performance).	
Discussion			
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	
Interpretation	19a	For validation, discuss the results with reference to performance in the development data, and any other validation data.	
	19b	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	
Implications	20	Discuss the potential clinical use of the model and implications for future research.	
Other information			
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	
Funding	22	Give the source of funding and the role of the funders for the present study.	

We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

BMJ Open

A comprehensive validation of very early rule-out strategies for non-ST-segment elevation myocardial infarction in emergency departments: protocol for a multicenter prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026985.R1
Article Type:	Protocol
Date Submitted by the Author:	04-Feb-2019
Complete List of Authors:	<p>Tada, Masafumi; Kyoto University, Graduate School of Medicine and School of Public Health</p> <p>Azuma, Hiroyuki; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Yamada, Naoki; Fukui University Hospital, Department of Emergency Medicine</p> <p>Kano, Ken-ichi; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Nagai, Hideya; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Maeda, Shigenobu; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Ishida, Hiroshi; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Aoyama, Takahiko; Fukui Prefectural Hospital, Cardiology, Vascular Center</p> <p>Okada, Ryota; Fukui University Hospital, Department of Emergency Medicine</p> <p>Kawano, Takahisa; Fukui University Hospital, Department of Emergency Medicine</p> <p>Kobuchi, Taketsune; Fukui University Hospital, Department of Emergency Medicine</p> <p>Uzui, Hiroyasu; Fukui University Hospital, Department of Cardiovascular Medicine</p> <p>Matano, Hideyuki; Fukui-ken Saiseikai Hospital, Department of Emergency Medicine</p> <p>Iwasaki, Hose; Fukui-ken Saiseikai Hospital, Department of Emergency Medicine</p> <p>Maeno, Koji; Fukui-ken Saiseikai Hospital, Department of Cardiology</p> <p>Shimada, Yoshimitsu; Japanese Red Cross Fukui Hospital, Department of Emergency Medicine</p> <p>Yoshida, Hiroyuki; Japanese Red Cross Fukui Hospital, Department of Cardiology</p> <p>Ando, Masaki; Nagoya City East Medical Center, Department of Emergency Medicine</p> <p>Murakami, Yoshimasa; Nagoya City East Medical Center, Department of Cardiovascular Medicine</p> <p>Iwakami, Naotsugu; National Cerebral and Cardiovascular Center,</p>

	<p>Department of Research Promotion and Management Kishimoto, Sanae; Kyoto University, Graduate School of Medicine and School of Public Health Iwami, Taku ; Kyoto University , Department of Health Service Tada, Hiroshi; Fukui University Hospital, Department of Cardiovascular Medicine Chapman, Andrew; University of Edinburgh, British Heart Foundation Center for Cardiovascular Science Mills, Nicholas; University of Edinburgh, British Heart Foundation Center for Cardiovascular Science Hayashi, Hiroyuki; Fukui University Hospital, Department of Emergency Medicine Furukawa, Toshi; Kyoto University, Graduate School of Medicine and School of Public Health Watanabe, Norio; Kyoto University, Graduate School of Medicine and School of Public Health</p>
Primary Subject Heading :	Emergency medicine
Secondary Subject Heading :	Cardiovascular medicine, Diagnostics
Keywords :	Myocardial infarction < CARDIOLOGY, troponin, ACCIDENT & EMERGENCY MEDICINE, Acute coronary syndrome

SCHOLARONE™
Manuscripts

1 **A comprehensive validation of very early rule-out strategies for non-ST-segment**
2 **elevation myocardial infarction in emergency departments: protocol for a multicenter**
3 **prospective cohort study**

4
5 Masafumi Tada,¹ Yoshida-konoecho, Sakyo-ku, Kyoto 606-8501 Japan

6 Correspondence to: tada.masafumi.76r@st.kyoto-u.ac.jp. Phone: +81-75-753-9491

7
8 Hiroyuki Azuma,² Naoki Yamada,⁴ Ken-ichi Kano,² Hideya Nagai,² Shigenobu Maeda,²

9 Hiroshi Ishida,² Takahiko Aoyama,³ Ryota Okada,⁴ Takahisa Kawano,⁴ Taketsune

10 Kobuchi,⁴ Hiroyasu Uzui,⁵ Hideyuki Matano,⁶ Hose Iwasaki,⁶ Koji Maeno,⁷ Yoshimitsu

11 Shimada,⁸ Hiroyuki Yoshida,⁹ Masaki Ando,¹⁰ Yoshimasa Murakami,¹¹ Naotsugu

12 Iwakami,¹² Sanae Kishimoto,¹ Taku Iwami,¹³ Hiroshi Tada,⁵ Andrew R. Chapman,¹⁴

13 Nicholas L. Mills,¹⁴ Hiroyuki Hayashi,⁴ Toshiaki Furukawa,¹ Norio Watanabe¹

14
15 **Author affiliations**

16 ¹ Department of Health Promotion and Human Behavior, Kyoto University Graduate

17 School of Medicine, Yoshida-konoecho, Sakyo-ku, Kyoto 606-8501, Japan

18 ² Department of Emergency Medicine, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui 910-

19 8526, Japan

20 ³ Cardiology, Vascular Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui 910-8526,

21 Japan

22 ⁴ Department of Emergency Medicine, Fukui University Hospital, 23-3

23 Matsuokashimoaizuki, Eihei-cho, Yoshida-gun, Fukui 910-1193, Japan

24 ⁵ Department of Cardiovascular Medicine, Fukui University Hospital, 23-3

25 Matsuokashimoaizuki, Eihei-cho, Yoshida-gun, Fukui 910-1193, Japan

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 ⁶ Department of Emergency Medicine, Fukui-ken Saiseikai Hospital, 7-1 Funabashi,
2 Wadanaka-cho, Fukui 918-8503, Japan

3 ⁷ Department of Cardiology, Fukui-ken Saiseikai Hospital, 7-1 Funabashi, Wadanaka-cho,
4 Fukui 918-8503, Japan

5 ⁸ Department of Emergency Medicine, Japanese Red Cross Fukui Hospital, 2-4-1 Tsukimi,
6 Fukui 918-8501, Japan

7 ⁹ Department of Cardiology, Japanese Red Cross Fukui Hospital, 2-4-1 Tsukimi, Fukui
8 918-8501, Japan

9 ¹⁰ Department of Emergency Medicine, Nagoya East Medical Center, 1-2-23 Wakamizu,
10 Chikusa-ku, Nagoya 464-8547, Japan

11 ¹¹ Department of Cardiovascular Medicine, Nagoya East Medical Center, 1-2-23
12 Wakamizu, Chikusa-ku, Nagoya 464-8547, Japan

13 ¹² Department of Research Promotion and Management, National Cerebral and
14 Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan

15 ¹³ Department of Health Services, Kyoto University, Yoshida-Honmachi, Sakyo-ku, Kyoto,
16 606-8501, Japan

17 ¹⁴ British Heart Foundation Center for Cardiovascular Science and Usher Institute of
18 Population Health Sciences and Informatics, University of Edinburgh, Chancellors
19 Building, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, United Kingdom

20 **Word count:** 4085

21 **Keywords:** myocardial infarction, high sensitivity troponin, clinical impression, prediction
22 rule

23

1 **ABSTRACT**

2 **Introduction**

3 Recent advances in troponin sensitivity enabled early and accurate judgement of ruling-out
4 myocardial infarction, especially non-ST elevation myocardial infarction (NSTEMI) in
5 emergency departments (ED) with development of various prediction-rules and high-
6 sensitive-troponin-based strategies (hs-troponin). Reliance on clinical impression, however,
7 is still common, and it remains unknown which of these strategies is superior. Therefore,
8 our objective in this prospective cohort study is to comprehensively validate the diagnostic
9 accuracy of clinical impression-based strategies, prediction-rules, and hs-troponin-based
10 strategies for ruling-out NSTEMIs.

12 **Methods and analysis**

13 In total, 1500 consecutive adult patients with symptoms suggestive of acute coronary
14 syndrome will be prospectively recruited from five EDs in two tertiary-, two secondary-
15 level community hospitals, and one university hospital in Japan. The study has begun in
16 July 2018, and recruitment period will be about one year. A board-certified emergency
17 physician will complete standardized case report forms, and independently perform a
18 clinical impression-based risk estimation of NSTEMI. Index strategies to be compared will
19 include: the clinical impression-based strategy; prediction rules; and hs-troponin-based
20 strategies for the following types of troponin (Roche Elecsys hs-troponin T; Abbott
21 ARCHITECT hs-troponin I; Siemens ADVIA Centaur hs-troponin I; Siemens ADVIA
22 Centaur sensitive-troponin I). The reference standard will be the composite of type 1 MI
23 and cardiac death within 30 days after admission to the ED. Outcome measures will be
24 NPV, sensitivity and effectiveness, defined as the proportion of patients categorized as low

1 risk for NSTEMI. We will also evaluate inter-rater reliability of the clinical impression-
2 based risk estimation.

3 **Ethics and dissemination**

4 The study is approved by the Ethics Committees of the Kyoto University Graduate School
5 and Faculty of Medicine and of the five hospitals where we will recruit patients.

6 **ARTICLE SUMMARY**

7 **Strengths and limitations of this study**

- 8 ■ This is the first prospective study to compare clinical impression-based strategies,
9 prediction-rules and hs-troponin-based strategies for ruling-out NSTEMI in patients
10 with symptoms suggestive of acute coronary syndrome in ED.
- 11 ■ We will also evaluate the inter-rater reliability of the clinical impression-based risk
12 estimation and discuss the usefulness of the strategies considering both the diagnostic
13 accuracy and the inter-rater reliability.
- 14 ■ We will use three high-sensitive-troponin and one sensitive-troponin which are
15 currently widely available in order to increase the applicability of the results of our
16 study.
- 17 ■ A limitation of the study is that troponin will rarely be taken later than three hours
18 after presentation to ED and we follow-up patients mainly by telephone interview, and
19 therefore, we may miss some subsequent MIs, although it is very unlikely that patients
20 will have a MI and not reattend hospital.
- 21 ■ Because the study population is only from Japan, the generalizability of the results
22 might be limited, although the prevalence of MI varies largely among previous studies
23 and that of our study will be somewhere among them.

1

2 INTRODUCTION

3 Background

4 Because ruling-out non-ST elevation myocardial infarctions (NSTEMI) is often
5 challenging, the American College of Cardiology (ACC) / American Heart Association
6 (AHA) and European Society of Cardiology (ESC) 2007 guidelines mandate the serial
7 troponin tests over a period of 6 to 12 h after symptom onset or admission to the emergency
8 department (ED).(1, 2) This long period of observation is the principal reason for admitting
9 patients with symptoms that might be related to an myocardial infarction (MI) and is, in
10 fact, the most frequent reason for admission in ED in both the United Kingdom and the
11 United States.(3, 4) However, between 75% and 95% of patients presenting to the EDs with
12 symptoms suggestive of MI did not have MI.(5, 6) Therefore, earlier and safer strategies to
13 rule-out an MI in EDs, which would allow patients to be discharged directly from the ED,
14 have been in a great demand. It is generally accepted that the risk of MI and death within
15 30 days should be less than one to two percent to patients directly discharged from the ED.
16 (7, 8)

17
18 Recently, several high-sensitive-troponins (hs-troponin) have decreased the recommended
19 time for troponin monitoring for MI diagnosis to 3-6 h (2014 ACC/AHA guidelines (9)),
20 and further to 0-3 h (2015 ESC guidelines (10)). Furthermore, a large individual patient-
21 level data meta-analysis reported that when the initial troponin value was much lower than
22 the 99th percentile, the negative predictive value (NPV) was consistently >99% across the
23 included cohorts.(6) Therefore, the time frame of serial troponin monitoring could be
24 greatly shortened, or even made unnecessary, for certain populations. The population in

1 East Asia may be appropriate for very early 'ruling-out' strategies of MI since the incidence
2 of MI in East Asia, especially in Japan, is much lower than in Western countries.(11)

3
4 Although troponin is crucial for the accurate diagnosis of MI, the clinical history, physical
5 findings and electrocardiogram (ECG) are also essential. Several clinical decision-making
6 models have been developed for MI, including the clinical impression-based strategy,
7 prediction rules and the hs-troponin-based strategy. The clinical impression-based strategy
8 is a traditional approach where clinical gestalt is used to estimate risk based on the history
9 and physical findings, and review of the ECG and troponin. Although few reports are
10 available, this approach remains common in practice, especially in Japan. However, the
11 inter-rater reliability of the risk estimation for MI based on clinical impression has not been
12 comprehensively evaluated, and previous studies suggested that risk estimation for MI
13 varies greatly, depending on the physician's experience and background.(12, 13)

14
15 Prediction rules have been developed that consider clinical findings and troponin
16 monitoring in a structured way to determine the risk of an MI. Several prediction rules to
17 estimate the risk of an MI have been defined, including the TIMI,(14) HEART,(15)
18 EDACS,(16) and T-MACS(17) rules. Most of the newer prediction rules that have
19 incorporated hs-troponin have achieved an NPV of >99% and have been validated.(18-21)
20 Prediction rules, however, are not widely used, despite their excellent NPVs, partly because
21 they have not been compared against clinical impression-based strategies.(22)

22
23 There are several hs-troponin-based strategies that use only hs-troponin, such as the 0 and
24 1h algorithm,(23) the 0 and 2h algorithm(24) and the High-STEACS pathway.(25) These
25 strategies are simple, and they rely on a measurement of hs-troponin only, with

1 demonstrated NPVs of >99%. Hs-troponin assays have excellent precision at very low
2 concentrations with very few analytical false positives.(26) On the other hand, the clinical
3 history, physical findings, and ECG readings are sometimes not reliable, and different
4 physicians often have different interpretations.(13, 27) Although they are essential
5 components of a comprehensive clinical assessment, the first risk stratification might be
6 better to be based on something that is highly reliable, with subsequent risk stratification
7 performed using clinical judgement, especially in ED where physicians with differing
8 backgrounds and experience work. However, the cutoffs of troponin levels in these hs-
9 troponin strategies tend to be much lower than the 99th percentile and patient age, which
10 has previously been associated with an increase in troponin level,(28, 29) may affect the
11 proportion of patients to be ruled-out. As such, hs-troponin-based strategies may be less
12 efficient in highly aged populations, such as in Japan.

13 **Rationale for the study**

14 First, although many strategies to rule-out MI have been proposed, a comprehensive
15 prospective validation of the clinical impression-based strategies, prediction-rules and hs-
16 troponin-based strategies to rule-out MI has not been performed.

17
18
19 Second, although the use of serial troponin and the cutoffs below the 99th percentile of
20 troponin are recommended in Western countries, it has not yet been proven well in East
21 Asia, where the incidence of MI is low and reliance on the clinical impression-based
22 strategy is common.(11) Because serial troponin is not only time consuming, but requires
23 additional resources and medical expenses, there is a need, particularly in East Asia, to
24 evaluate the NPV of clinical impression-based strategies, combined with troponin levels
25 obtained at different time points, using the 99th percentile cutoff value.

1
2
3
4
5
6 1
7
8 2 Third, although many kinds of troponins are now available, the diagnostic accuracy and
9
10 3 cutoff are each troponin specific. Our proposed study will include the four types of troponin
11
12 4 that are currently widely available: Roche hs-troponin T; Abbott hs-troponin I; Siemens hs-
13
14 5 troponin I; Siemens sensitive-troponin I in order to increase the applicability of our results
15
16 6 to as many facilities as possible.
17
18 7

8 **Study objectives**

9 1. Primary research objective

10 Our primary objective is to compare the NPV, sensitivity and effectiveness (defined as the
11
12 11 proportion of patients categorized into low risk to all patients to whom a strategy was
13
14 12 applied) of the three clinical impression-based strategies with three time frames of troponin
15
16 13 monitoring: on arrival (0 h) only; 0 h and 1 h after; and 0 h and 2 h after, using the
17
18 14 composite outcome of cardiac death or the occurrence of a type 1 MI within 30 days of the
19
20 15 ED consultation.
21
22 16

17 2. Secondary research objectives

18 Our secondary research objectives are:

19 2.1. To validate and compare the NPV, sensitivity and effectiveness between clinical
20
21 20 impression-based strategies, prediction rules and hs-troponin-based strategies.

22 2.2. To evaluate the inter-rater reliability of the clinical impression-based strategy, in
23
24 22 estimating the risk estimation of an MI, when performed by board certified emergency
25
26 23 physicians and senior residents of emergency medicine, general internists, cardiologists,
27
28 24 junior residents, and nurses.
29
30 25

1 **METHODS AND ANALYSIS**

2 **Setting**

3 We will recruit patients from five EDs in two tertiary-level community hospitals (Fukui
4 Prefectural Hospital, Nagoya East Medical Center), two secondary-level community
5 hospitals (Fukui-ken Saiseikai Hospital, Japanese Red Cross Fukui Hospital) and one
6 university hospital (Fukui University Hospital) in Japan. We will recruit further hospitals in
7 other regions in Japan

9 **Inclusion criteria**

- 10 1. Age ≥ 25 years
- 11 2. Have any one of the following symptoms suspected to be MI
12 Chest pain
13 Non-chest pain, including radiating pain, syncope, dyspnea, nausea / vomiting, and
14 fatigue, and other symptoms which emergency physicians judge to need to rule out
15 an MI
- 16 3. Presentation to the ED within 6 hours from symptom onset. We will set the threshold
17 at six hours to focus on early presenters, the most difficult population to rule-out
18 NSTEMI very early (30)
- 19 4. No apparent ST elevation on arrival
- 20 5. The use of both ECG and the troponin test, as deemed to be required by the ED
21 physician

23 **Exclusion criteria**

- 24 1. Cardiopulmonary arrest on arrival
- 25 2. Non-cardiac terminal illness (expected survival less than six months)

- 1 3. Need for resuscitation (physiological shock, continuous oxygen administration)
- 2 4. Indication of emergency catheterization on arrival
- 3 5. Inability of the patient to provide consent
- 4 6. Previous inclusion in the study
- 5 7. Unable to contact for follow-up after 30 days
- 6 8. Unknown time of onset of symptoms
- 7 9. Apparent need to admit for a diagnosis other than acute coronary syndrome on arrival
- 8 10. Patients on maintenance dialysis
- 9 11. Judged as ineligible by an emergency physician

10

11 **Participants recruitment**

12 When an MI is suspected, an ECG will be obtained first, as per usual practice. If there is no
13 significant ST elevation, a board-certified emergency physician will assess the eligibility of
14 the patient for enrollment into the study. Because board-certified emergency physicians are
15 not regularly available at night or on weekends in three of the participating hospitals
16 (Fukui-ken Saiseikai Hospital; Japanese Red Cross Fukui Hospital; and Nagoya East
17 Medical Center), patients will only be recruited when board-certified emergency physicians
18 are working in these centers. In the other two facilities (Fukui Prefectural Hospital and
19 Fukui University Hospital), board-certified emergency physicians are available around the
20 clock and, therefore, patients will be recruited as they present to the EDs.

21

22 **Informed consent**

23 We will obtain written informed consent from all patients. Because MI is more common in
24 the elderly, it may be sometimes difficult to obtain informed consent from some patients
25 due to dementia. Because excluding these patients will impair the validity of the study, we

1 will seek to obtain consent from patient's authorized proxy in such cases. We will conduct
2 this study in accordance with the Declaration of Helsinki and its amendments. This study is
3 registered in the UMIN-CTR registry (UMIN 000029992).

4 **Clinical assessments**

5 The following assessments will be performed at each site using standardized case report
6 forms (CRF): history; physical examination; clinical impression-based risk estimation;
7 ECG; standard blood tests; ultrasonography; and troponin levels (using both in-house and
8 research troponin types). Clinical impression-based risk estimation for a NSTEMI will be
9 classified as low, intermediate or high for analysis. The certainty of each item of the
10 clinical history and ECG will be measured using a 4-point Likert scale. The inter-rater
11 reliability will be evaluated between a board-certified emergency physician and one of the
12 following medical staff: a board-certified emergency physician; an emergency medicine
13 resident; a junior resident; a general practitioner; a cardiologist; or a nurse for 300
14 consecutive patients enrolled into the study. The following variables will be included for
15 inter-rater reliability: clinical impression-based risk estimation; each item of the clinical
16 history; ECG; ultrasonography. Assessors will not be provided with results of the troponin
17 levels, ultrasonography examination or the previous assessment performed by another
18 emergency physician or cardiologist before completion of the CRF. Because it will
19 occasionally be difficult to mask this information, we will report the masking status.
20 Management of patients will be left to the discretion of treating emergency physicians and
21 cardiologists, based on the results of in-house troponin measurements in each hospital. The
22 indication of early invasive strategy will follow current guidelines. (9, 10, 31)

24 **Troponin**

1 We will evaluate the following four types of troponin, three high-sensitive and one
 2 sensitive. The 99th percentile and the limit of detection (LoD) values for the four types of
 3 troponin are summarized in Table 1. We will use sex-specific 99th percentile values for
 4 three types of hs-troponin in sensitivity analyses. We will collect blood samples in serum
 5 tubes for troponin levels on arrival (0 h); and at one hour (1 h), two hours (2 h), and three
 6 hours (3 h) after the first blood draw. After centrifugation, serum samples will be stored at
 7 less than -20°C until measured in each manufacturer's laboratory in a blinded fashion.

8
 9 Table 1 The 99th percentile and LoD values for four types of troponin

Troponin	99th percentile (ng/L)	LoD (ng/L)
Roche Elecsys hs-troponin T (general)	14.0	3.0
Roche Elecsys hs-troponin T (male)	15.5	
Roche Elecsys hs-troponin T (female)	9.0	
Abbott ARCHITECT hs-troponin I (general)	26.2	1.9
Abbott ARCHITECT hs-troponin I (male)	34.2	
Abbott ARCHITECT hs-troponin I (female)	15.6	
Siemens ADVIA Centaur hs-troponin I (general)	46.5	2.2
Siemens ADVIA Centaur hs-troponin I (male)	58.1	
Siemens ADVIA Centaur hs-troponin I (female)	39.6	
Siemens ADVIA Centaur sensitive-troponin I	40.0	6.0

10 LoD indicates limit of detection

11

12 **Index tests**

1 We will evaluate the three types of decision-making models to rule-out MI: the clinical
2 impression-based strategies, prediction rules, and hs-troponin-based strategies. An author
3 (MT) searched PubMed (December 2017) for prediction rules and hs-based strategies to
4 rule-out MI in ED. We also consulted reviews on this topic to identify suitable decision-
5 making models. Among identified prediction-rules and hs-troponin-based strategies, we
6 selected those which were validated and showed an NPV of >99%, using any types of
7 troponin. We will include strategies with troponin taken up to two hours apart from the first
8 one. Because it generally takes about one hour to take the first blood sample, we will
9 include strategies with troponin taken up to three hours from presentation. All the intervals
10 of troponin sampling we showed below are the time from the first blood draw. Each
11 troponin will be adapted for each strategy, as needed. We will define the troponin cutoff at
12 the 99th percentile value, except for hs-troponin-based strategies, and the T-MACS. The
13 troponin cutoffs for hs-troponin-based strategies are specific for each type of troponin, as
14 detailed below. Troponin values will be incorporated as a continuous variable in the T-
15 MACS. We will adopt cutoffs for each strategy in accordance with the original publication
16 for each strategy.

18 The clinical impression-based strategies

19 1. The 0 h model

- 20 1) Clinical impression-based risk estimation for history and physical findings is not high
21 risk
- 22 2) No new ischemic findings on ECG
- 23 3) Troponin taken on arrival is below the 99th percentile

25 2. The 0 h and 1 h model

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1) Clinical impression-based risk estimation for history and physical findings is not high risk
 - 2) No new ischemic findings on ECG
 - 3) Troponin taken on arrival and at 1 h apart are both below the 99th percentile
3. The 0 h and 2 h model
- 1) Clinical impression-based risk estimation for history and physical findings is not high risk
 - 2) No new ischemic findings on ECG
 - 3) Troponin taken on arrival and at 2 h apart are both below the 99th percentile

We will evaluate the clinical impression-based risk estimation for history and physical findings based on the AHA/ACC guideline(32) and a systematic review.(33) We define the new ischemic findings on ECG as an ST depression and negative T wave not known to be old. An ST depression is defined by a depression of 0.05mV or more at J point in two or more contiguous leads. A negative T wave is defined by T wave inversions of 0.1mV or more in two or more contiguous leads. If all three components of each model are satisfied, we regard a patient as being at low risk for an MI. The details of each prediction rule are shown in the online supplementary appendix.

Prediction rules

1. TIMI + 2 h troponin(34)

Components: age, coronary risk factors, use of aspirin, significant coronary stenosis, severe angina, ECG, and troponin (at 0 and 2 h)

Cutoff: we will define the score of 0 as a low risk for MI

1 2. HEART(15)

2 Components: history, ECG, age, risk factors, and troponin

3 Cutoff: we will define the score of 0-3 and negative troponin as a low risk for MI

4 3. EDACS(16)

5 Components: age, sex, coronary artery disease or risk factors, symptoms, ECG, and
6 troponin (at 0 and 2 h)

7 Cutoff: we will define low risk when all three conditions are satisfied, namely: a score <
8 16; no new ischemia on ECG; and negative troponin at 0 and 2 h

9 4. T-MACS(17)

10 Components: (E) ECG ischemia, (A) Worsening or crescendo angina, (R) Right arm or shoulder pain,
11 (V) Vomiting, (S) Sweating observed, (H) Hypotension (systolic blood pressure < 100 mm Hg)
12 (T) High-sensitivity troponin T concentration on arrival (ng/L)

13 Probability = $1 / (1 + e^{-(1.713E + 0.847A + 0.607R + 1.417V + 2.058S + 1.208H + 0.089T - 4.766)})$

14 Cutoff: we will define low risk if the probability is <0.02

15 5. TRUST(35)

16 Components: typical new-onset chest pain at rest, pain the same as previous MI, pain not
17 relieved by glyceryl trinitrate within 15 min, pain lasting more than 60 min,
18 pain occurring with increasing frequency, hypotension, acute shortness of breath,
19 pain within 6 weeks of an MI or revascularization, ECG, hs-troponin (at 0 h)

20 Cutoff: we will define low risk when all three conditions are satisfied: the score of 0 or 1,
21 non-ischemic ECG, and negative troponin

22 6. GRACE(10)

23 Components: age, history of congestive heart failure, history of myocardial infarction,

1 resting heart rate, systolic blood pressure, ST-segment depression, initial serum
 2 creatinine, elevated cardiac enzymes, no in-hospital percutaneous coronary
 3 intervention

4 Cutoff: we will define the score less than 140 AND negative troponin at 0 and 2 h

6 Hs-troponin-based strategies

7 Hs-troponin-based strategies are comprised of hs-troponin only, with cutoff values being
 8 troponin specific, as shown below for the five algorithms that will be used in the study. If a
 9 troponin value is below the cutoff values of each strategy, we regard a patient as being at
 10 low risk for an MI. In the High-STEACS pathway, a second troponin measurement is
 11 obtained three hours from presentation to the ED.(25) Because there is often a delay of up
 12 to one hour for the first blood sample, the average time between the first and second
 13 troponin measurement is two hours, and therefore, we include the High-STEACS pathway
 14 without modification.

16 1. The 0 h algorithm(36, 37)

17 Roche hs-troponin T: 0 h <5 ng/L(*1)

18 Abbott hs-troponin I: 0 h <2 ng/L(*2)

19 Siemens hs-troponin I: 0 h <3 ng/L(*3)

20 Siemens sensitive-troponin I: 0 h <0.5 ng/L(*4)

22 2. The 1 h algorithm(23, 37-39)

23 Roche hs-troponin T: 0 h <12 ng/L AND Δ 0-1 h <3 ng/L(*5)

24 Abbott hs-troponin I: 0 h <5 ng/L AND Δ 0-1 h <2 ng/L(*6)

25 Siemens hs-troponin I: 0 h <6 ng/L AND Δ 0-1 h <3 ng/L(*7)

1 Siemens sensitive-troponin I: 0 h <10 ng/L AND Δ 0-1 h <4 ng/L^(*8)

2

3 3. The 2 h algorithm(24, 39, 40)

4 Roche hs-troponin T: 0 and 2 h <14 ng/L AND Δ 0-2 h <4 ng/L

5 Abbott hs-troponin I: 0 and 2 h <6 ng/L AND Δ 0-2 h <2 ng/L

6 Siemens sensitive-troponin I: 0 and 2 h <10 ng/L

7

8 4. The 0 and 1h algorithm(10, 37)

9 Roche hs-troponin T: *1 OR *5

10 Abbott hs-troponin I: *2 OR *6

11 Siemens hs-troponin I: *3 OR *7

12 Siemens sensitive-troponin I: *4 OR *8

13

14 5. The High-STEACS pathway (only for Abbott hs-troponin I at the moment) (25)

15 If hs-troponin I at 0 h <5 ng/L AND symptom onset \geq 2 h, AMI is ruled out.

16 If $5 \leq$ hs-troponin I at 0 h \leq 26.2 ng/L OR symptom onset <2 h, hs-troponin I at 2 h is

17 required. If Δ 0-2 h hs-troponin I <3ng/L AND hs-troponin I at 3 h \leq 26.2 ng/L, AMI is

18 ruled out.

19

20 **Reference standard**

21 **Final diagnosis adjudication**

22 Two cardiologists of each facility will independently adjudicate the final diagnosis based

23 on the results of the follow-up telephone interview and all available clinical information

24 obtained 30 days or more after the admission to the ED: each item of the clinical history;

1 physical examination; laboratory tests (both in-house troponin and hs-troponin T taken at 0
2 and 3 h); ECG; ultrasonography; cardiac stress test; radiological test; and coronary
3 angiography. Disagreements will be resolved through discussions between the two
4 cardiologists. If they are unable to reach consensus, a third cardiologist will be consulted.
5 All cardiologists will be masked from the results of index tests and the research hs-troponin
6 obtained at 1 and 2 h.

7 The diagnosis of MI will be made in accordance with the forth universal definition of
8 myocardial infarction,(41) and classified as type 1, type 2, type 4b, and myocardial injury.
9 Briefly, an MI will be diagnosed if there is a significant rise and/or fall of troponin, with at
10 least one value above the 99th percentile, in a clinical setting consistent with acute
11 myocardial ischemia. We will adjudicate final diagnosis with each of hs-troponin assays
12 (Roche hs-troponin T, Abbott hs-troponin I, and Siemens hs-troponin I). We will use the
13 same hs-troponin to adjudicate the final diagnosis as that used for index tests to avoid
14 unequal incorporation bias. We will define a significant rise and/or fall for three hours as 6
15 ng/L for Roche hs-troponin T; the relative increase of >50% of the respective 99th
16 percentile value if the initial troponin value is equal or less than the 99th percentile value,
17 and the relative increase of >20% of the initial value if the initial troponin values is greater
18 than the 99th percentile value for Abbott hs-troponin I and Siemens hs-troponin I.(23, 26)
19 Type 1 MI is defined as myocardial necrosis with symptoms suggestive of MI or test results
20 which prove myocardial ischemia. Type 2 MI is defined as myocardial necrosis, with a
21 condition other than coronary artery disease, which contributes to an oxygen supply-
22 demand imbalance (e.g. coronary artery spasm; tachyarrhythmia; respiratory failure; or
23 anemia). Type 4b is an MI associated with stent thrombosis.

24 25 [Clinical outcomes](#)

1 The primary clinical outcome will be the composite of type 1 MI and cardiac death within
2 30 days of the ED admission. If patients consult an ED or cardiac service in the study
3 facility again, emergency physicians or cardiologists will ask patients if they have had an
4 MI or if they have undergone any cardiac tests or revascularization in other hospitals.
5 Because not all patients can be expected to consult a study facility again, research staffs
6 will conduct structured telephone follow-up interview with all patients enrolled into the
7 study, 30 days after the ED admission. At 30 days, if patients have either consulted a study
8 facility again or if sufficient clinical information is available, we will include only type 1
9 MI as the primary clinical outcome. Whilst for patients who do not consult a study facility
10 again and, therefore, only information from the telephone follow-up is for clinical
11 outcomes, it will be difficult to differentiate type 1 MI from other types of MI. In these
12 cases, we will include all MI types (1, 2 and 4b) as the primary clinical outcome. Similarly,
13 the adjudication of a cause of death might be difficult in some patients. In this case, we will
14 include an unknown cause of death into our primary outcome. Patients who do not consult a
15 study facility again and could not be reached for the telephone follow-up interview will be
16 excluded from the primary and secondary research objectives.

17

18 **Sample size calculation**

19 Assuming that the event rate of the primary clinical outcome is 5 to 10%,(6, 11) with a
20 sensitivity and specificity of the clinical impression-based strategies of 95% and 55%,
21 respectively,(42) 1500 patients will need to be enrolled into the study if the lower limit of
22 95% CI of the NPV is to surpass 98%.

23

24 **Data analysis**

25 **Primary research objective**

1 We will describe the NPV, sensitivity and effectiveness of the three clinical impression-
2 based strategies, using the 95%CI for each troponin. We will also calculate the specificity,
3 positive predictive value, and area under the receiver operating characteristic curve (AUC)
4 for each strategy. We will derive a generalized score statistic to compare NPV, and use the
5 McNemar test to compare sensitivity and effectiveness. We will regard a strategy as being
6 clinically useful if the point estimate for NPV is $\geq 99\%$. If the point estimate for NPV is
7 $\geq 99\%$, we will regard a strategy with shorter observational period as superior.

8 9 **Secondary research objective 1**

10 We will describe the NPV, sensitivity, effectiveness, AUC for the clinical impression-based
11 strategies, prediction rules, and hs-troponin-based strategies for each troponin. If the point
12 estimate for NPV is $\geq 99\%$, we will regard a strategy with higher effectiveness and / or
13 shorter observational period as superior.

14 15 **Secondary research objective 2**

16 Reliability will be evaluated for 300 consecutive patients. We will use Cohen's weighted
17 Kappa-statistic and the boot-strap method, with 1000 replications, to determine the 95% CI
18 boundaries of reliability.

19 20 **Sensitivity analysis**

21 A sensitivity analysis will be performed including type 2 and 4b MI to the primary clinical
22 outcome. We will compare the NPV, sensitivity and effectiveness of the index tests
23 between subgroups stratified by: time from symptom onset to hospital arrival; the clinical
24 impression-based risk estimation; past history of ischemic heart disease or
25 revascularization; age; sex; and presence of chest pain considering its certainty. We will

1 define the cutoff of the clinical impression-based risk estimation as neither moderate nor
2 high. We also perform analyses by changing the cutoffs of other strategies. We will
3 combine the hs-troponin-based strategies with clinical impression-based risk estimation
4 and/or ECG, and evaluate the NPV, sensitivity, and effectiveness. We will use each of
5 Roche Elecsys hs-troponin T; Siemens ADVIA Centaur hs-troponin I; and Siemens
6 ADVIA Centaur sensitive-troponin I for the adjudication of MI. We will use sex-specific
7 99th percentiles of three types of hs-troponin for the index tests.

8 9 **Ethics and dissemination**

10 This study is approved by the Ethics Committees of the Kyoto University Graduate School
11 and Faculty of Medicine (R1380, 27 February 2018) and the five hospitals where we will
12 recruit patients. We will disseminate the results of the study through peer-reviewed journals
13 and conference presentations. For the study participants, we will disseminate the brief
14 summary of the results of the study to all the EDs of study hospitals.

15 16 **Patient and public involvement**

17 No patients were asked for input in the creation of this article.

18 19 **Summary**

20 Along with the advance in troponin monitoring, the early management of MI suspected
21 patients is markedly changing. Though many troponins are available now, diagnostic
22 accuracy and cutoff values are specific for each type of troponin. Although many
23 prediction-rules and hs-troponin-based strategies have been published, it is still unknown if
24 these algorithms are superior to clinical impression-based strategies. The study will be the
25 first prospective study to compare clinical impression-based strategies, using four different

1 types of troponin that are commonly used to estimate the risk of an MI with prediction-
2 rules and hs-troponin-based strategies. We will also evaluate the inter-rater reliability of the
3 clinical impression-based risk estimation, and discuss the usefulness of these strategies,
4 considering both the diagnostic accuracy and the inter-rater reliability.

6 **Acknowledgments**

7 The authors sincerely thank the patients who are participating in the study. The authors
8 warmly thank emergency physicians, S. Tanizaki, M. Sera, M. Hayashi, T. Nakanishi, H.
9 Watanabe, and J. Tanaka in Fukui prefectural hospital; T. Kimura, H. Morita, T.
10 Yamanaka, T. Hamada, H. Tsuji, Y. Kuwabara, Y. Kamikawa in Fukui university hospital;
11 M. Inagaki, T. Miura, T. Ohno in Nagoya east medical center. The authors would like to
12 thank cardiologists, S. Fujino, M. Yamaguchi, Y. Noji, H. Kato, R. Yamamura, N. Ukawa,
13 Y. Takahashi in Fukui prefectural hospital; S. Miyazaki, K. Ishida, K. Kaseno, K.
14 Hasegawa, T. Morishita, Y. Fukuoka, H. Ikeda, N. Tama, Y. Shiomi, J. Yamaguchi, D.
15 Aoyama, T. Aiki, E. Ishikawa, M. Mukai, A. Matsui, K. Miyahara in Fukui university
16 hospital; H. Takemori, K. Ohkura, M. Hirazawa, S. Ohkura, H. Tsuneyama in Fukui-ken
17 Saiseikai hospital; T. Akiyoshi, K. Sarazawa, K. Sakakibara, J. Yamaguchi, T. Kataoka in
18 Japanese red cross Fukui hospital; T. Saeki, N. Tamai, S. Yamashita, T. Yoshida, T.
19 Sekimoto, K. Hachiya, T. Hasuo, T. Hashimoto, T. Noda in Nagoya east medical center.
20 The authors also thank general physicians, residents, nurses, and clinical technologists of
21 the five study hospitals for their voluntary co-operation. The authors acknowledge clinical
22 laboratory technologists of the five study hospitals for blood sample handling; and the
23 Roche and T. Kikuchi, the Abbott and S. Sugawa, and the Siemens and T. Yokoyama for
24 biomarker measurement including troponin. The authors also appreciate K. Yamamoto and
25 the Union Think for offering an optical character recognition program to incorporate data

1 of paper CRF into REDCap (version 8.1.17; Nashville, TN) electronic data capturing
2 system.

3 4 **Author contributions**

5 MT, NW wrote the first draft. All other authors, HA, NY, KK, HN, SM, HI, TA, RO, TK,
6 TK, HU, HT, HM, HI, KM, YS, HY, MA, YM, NI, SK, TI, HT, AC, NM, HH and TF
7 contributed to the conception and design of the study. All the authors read and approved the
8 final manuscript.

9 10 **Funding**

11 The study is supported by grants from Nakatani Foundation (Tokyo, Japan), and from
12 Radiometer (Tokyo, Japan).

13 14 **Competing interests**

15 MT received non-financial support from Roche, Abbott, and Siemens during the conduct of
16 the study; personal fees from Japan Medical Journal, outside the submitted work. ARC has
17 received honoraria from Abbott Diagnostics and AstraZeneca. NLM has received honoraria
18 and consultancy from Abbott Diagnostics, Roche Diagnostics and Singulex. TF reports
19 personal fees from Meiji Seika, grants and personal fees from MSD, personal fees from
20 Pfizer, outside the submitted work. NW has received research funds from the Japanese
21 Ministry of Health Labor and Welfare, the Japanese Ministry of Education, Science, and
22 Technology and National Center of Neurology and Psychiatry, Intramural Research Grant
23 for Neurological and Psychiatric Disorders. He has also received royalties from Sogensha
24 and Akatsuki. All other authors report no conflicts.

1 REFERENCES

- 1 1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the
2 management of patients with unstable angina/non ST-elevation myocardial infarction: a
3 report of the American College of Cardiology/American Heart Association Task Force on
4 Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the
5 Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction):
6 developed in collaboration with the American College of Emergency Physicians, the
7 Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic
8 Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary
9 Rehabilitation and the Society for Academic Emergency Medicine. *Circulation*.
10 2007;116(7):e148-304.
- 11 2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and
12 treatment of non-ST-segment elevation acute coronary syndromes. *Eur Heart J*.
13 2007;28(13):1598-660.
- 14 3. Niska R, Bhuiya F, Xu J. National Hospital Ambulatory Medical Care Survey:
15 2007 emergency department summary. *Natl Health Stat Report*. 2010(26):1-31.
- 16 4. The Health and Social Care Information Centre. Hospital Episode Statistics,
17 Admitted Patient Care—England, 2013-14: Primary diagnosis, 3 characters table. URL:
18 [https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-](https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/hospital-episode-statistics-admitted-patient-care-england-2013-14#resources)
19 [patient-care-activity/hospital-episode-statistics-admitted-patient-care-england-2013-](https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/hospital-episode-statistics-admitted-patient-care-england-2013-14#resources)
20 [14#resources](https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/hospital-episode-statistics-admitted-patient-care-england-2013-14#resources) Date of access: Jan. 30 2019
- 21 5. Hollander JE, Than M, Mueller C. State-of-the-Art Evaluation of Emergency
22 Department Patients Presenting With Potential Acute Coronary Syndromes. *Circulation*.
23 2016;134(7):547-64.
- 24 6. Chapman AR, Lee KK, McAllister DA, et al. Association of High-Sensitivity
25 Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected
26 Acute Coronary Syndrome. *JAMA*. 2017;318(19):1913-24.
- 27 7. Miller C. Evaluation of patients with chest pain at low or intermediate risk for
28 acute coronary syndrome. Up To Date. URL:
29 <https://www.uptodate.com/contents/evaluation-of-patients-with-chest-pain-at-low-or->
30

- 1 [intermediate-risk-for-acute-coronary-](#)
2 [syndrome?search=Evaluation%20of%20patients%20with%20chest%20pain%20at%20low](#)
3 [%20or%20intermediate%20risk%20for%20acute%20coronary%20syndrome.&source=sear](#)
4 [ch_result&selectedTitle=1~150&usage_type=default&display_rank=1](#) Date of access: Jan.
5 30 2019
- 6 8. Mahler SA, Miller CD, Hollander JE, et al. Identifying patients for early
7 discharge: performance of decision rules among patients with acute chest pain. *Int J*
8 *Cardiol.* 2013;168(2):795-802.
- 9 9. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for
10 the management of patients with non-ST-elevation acute coronary syndromes: a report of
11 the American College of Cardiology/American Heart Association Task Force on Practice
12 Guidelines. *Circulation.* 2014;130(25):e344-426.
- 13 10. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of
14 acute coronary syndromes in patients presenting without persistent ST-segment elevation:
15 Task Force for the Management of Acute Coronary Syndromes in Patients Presenting
16 without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
17 *Eur Heart J.* 2016;37(3):267-315.
- 18 11. Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors
19 in Asia: a selected review. *Circulation.* 2008;118(25):2702-9.
- 20 12. Hess EP, Brison RJ, Perry JJ, et al. Development of a clinical prediction rule for
21 30-day cardiac events in emergency department patients with chest pain and possible acute
22 coronary syndrome. *Ann Emerg Med.* 2012;59(2):115-25 e1.
- 23 13. Wu WK, Yiadom MY, Collins SP, et al. Documentation of HEART score
24 discordance between emergency physician and cardiologist evaluations of ED patients with
25 chest pain. *Am J Emerg Med.* 2017;35(1):132-5.
- 26 14. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable
27 angina/non-ST elevation MI: A method for prognostication and therapeutic decision
28 making. *JAMA.* 2000;284(7):835-42.
- 29 15. Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the
30 HEART score. *Netherlands heart journal : Neth Heart J.* 2008;16(6):191-6.

- 1
2
3
4
5
6 16. Than M, Flaws D, Sanders S, et al. Development and validation of the
7 Emergency Department Assessment of Chest pain Score and 2 h accelerated diagnostic
8 protocol. *Emerg Med Australas*. 2014;26(1):34-44.
9
10 17. Body R, Carlton E, Sperrin M, et al. Troponin-only Manchester Acute Coronary
11 Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation
12 in three cohorts. *Emerg Med J*. 2017;34(6):349-56.
13
14 18. Cullen L, Mueller C, Parsonage WA, et al. Validation of high-sensitivity troponin
15 I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department
16 patients with possible acute coronary syndrome. *J Am Coll Cardiol*. 2013;62(14):1242-9.
17
18 19. Meller B, Cullen L, Parsonage WA, et al. Accelerated diagnostic protocol using
19 high-sensitivity cardiac troponin T in acute chest pain patients. *Int J Cardiol*.
20 2015;184:208-15.
21
22 20. McCord J, Cabrera R, Lindahl B, et al. Prognostic Utility of a Modified HEART
23 Score in Chest Pain Patients in the Emergency Department. *Circ Cardiovasc Qual*
24 *Outcomes*. 2017;10(2).
25
26 21. Carlton EW, Khattab A, Greaves K. Identifying Patients Suitable for Discharge
27 After a Single-Presentation High-Sensitivity Troponin Result: A Comparison of Five
28 Established Risk Scores and Two High-Sensitivity Assays. *Ann Emerg Med*.
29 2015;66(6):635-45 e1.
30
31 22. Adams ST, Leveson SH. Clinical prediction rules. *BMJ*. 2012;344:d8312.
32
33 23. Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute
34 myocardial infarction using high-sensitivity cardiac troponin T. *Arch Intern Med*.
35 2012;172(16):1211-8.
36
37 24. Reichlin T, Cullen L, Parsonage WA, et al. Two-hour algorithm for triage toward
38 rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin
39 T. *Am J Med*. 2015;128(4):369-79 e4.
40
41 25. Chapman AR, Anand A, Boeddinghaus J, et al. Comparison of the Efficacy and
42 Safety of Early Rule-Out Pathways for Acute Myocardial Infarction. *Circulation*.
43 2017;135(17):1586-96.
44
45 26. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac

- 1 troponins in acute cardiac care. *Eur Heart J*. 2012;33(18):2252-7.
- 2 27. Body R, Carley S, Wibberley C, et al. The value of symptoms and signs in the
3 emergent diagnosis of acute coronary syndromes. *Resuscitation*. 2010;81(3):281-6.
- 4 28. Riedlinger D, Mockel M, Muller C, et al. High-sensitivity cardiac troponin T for
5 diagnosis of NSTEMI in the elderly emergency department patient: a clinical cohort study.
6 *Biomarkers*. 2018;23(6):551-7.
- 7 29. Welsh P, Preiss D, Shah ASV, et al. Comparison Between High-Sensitivity
8 Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. *Clin
9 Chem*. 2018;64(11):1607-1616.
- 10 30. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial
11 infarction with sensitive cardiac troponin assays. *N Engl J Med*. 2009;361(9):858-67.
- 12 31. Kimura T, Issiki T, Ohno T, et al. Guidelines for Management of Acute Coronary
13 Syndrome without Persistent ST Segment Elevation (JCS 2012). URL: [http://www.j-
14 circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf](http://www.j-circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf) Date of access: Jan. 30 2019
- 15 32. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the
16 management of patients with unstable angina/non-ST-Elevation myocardial infarction: a
17 report of the American College of Cardiology/American Heart Association Task Force on
18 Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the
19 Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction)
20 developed in collaboration with the American College of Emergency Physicians, the
21 Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic
22 Surgeons endorsed by the American Association of Cardiovascular and Pulmonary
23 Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol*.
24 2007;50(7):e1-e157.
- 25 33. Fanaroff AC, Rymer JA, Goldstein SA, et al. Does This Patient With Chest Pain
26 Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review.
27 *JAMA*. 2015;314(18):1955-65.
- 28 34. Than M, Cullen L, Aldous S, et al. 2-Hour accelerated diagnostic protocol to
29 assess patients with chest pain symptoms using contemporary troponins as the only
30 biomarker: the ADAPT trial. *J Am Coll Cardiol*. 2012;59(23):2091-8.

- 1
2
3
4
5
6 1 35. Carlton EW, Cullen L, Than M, et al. A novel diagnostic protocol to identify
7 2 patients suitable for discharge after a single high-sensitivity troponin. *Heart*.
8 3 2015;101(13):1041-6.
9
10 4 36. Rubini Gimenez M, Hoeller R, Reichlin T, et al. Rapid rule out of acute
11 5 myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. *Int J*
12 6 *Cardiol*. 2013;168(4):3896-901.
13
14 7 37. Boeddinghaus J, Twerenbold R, Nestelberger T, et al. Clinical Validation of a
15 8 Novel High-Sensitivity Cardiac Troponin I Assay for Early Diagnosis of Acute Myocardial
16 9 Infarction. *Clin Chem*. 2018;64(9):1347-1360.
17
18 10 38. Rubini Gimenez M, Twerenbold R, Jaeger C, et al. One-hour rule-in and rule-out
19 11 of acute myocardial infarction using high-sensitivity cardiac troponin I. *Am J Med*.
20 12 2015;128(8):861-70 e4.
21
22 13 39. Druey S, Wildi K, Twerenbold R, et al. Early rule-out and rule-in of myocardial
23 14 infarction using sensitive cardiac Troponin I. *Int J Cardiol*. 2015;195:163-70.
24
25 15 40. Boeddinghaus J, Reichlin T, Cullen L, et al. Two-Hour Algorithm for Triage
26 16 toward Rule-Out and Rule-In of Acute Myocardial Infarction by Use of High-Sensitivity
27 17 Cardiac Troponin I. *Clin Chem*. 2016;62(3):494-504.
28
29 18 41. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial
30 19 infarction (2018). *Eur Heart J*. 2019;40(3):237-269.
31
32 20 42. Body R, Cook G, Burrows G, et al. Can emergency physicians 'rule in' and 'rule
33 21 out' acute myocardial infarction with clinical judgement? *Emerg Med J*. 2014;31(11):872-6.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary appendix

The components of prediction rules

1. TIMI + 2 h troponin (34)

- 1) Troponin level at 0 and 2 h below 99th percentile value
- 2) No new ischemic changes on the initial ECG
- 3) TIMI score = 0 (all items below have to be negative)
 - a. Age ≥ 65 years
 - b. Three or more risk factors for coronary artery disease
(family history of coronary artery disease, hypertension, hypercholesterolaemia, diabetes, or being in a current smoker)
 - c. Use of aspirin in the past 7 days
 - d. Significant coronary stenosis (previous coronary stenosis $\geq 50\%$)
 - e. Severe angina (≥ 2 angina events in past 24 h or persistent discomfort)
 - f. ST-segment deviation of ≥ 0.05 mV on first ECG
 - g. Increased troponin

Low risk: all parameters, 1), 2), and 3) are satisfied

2. HEART (15)

		score
1) History	Highly suspicious	2
	Moderately suspicious	1
	Slightly suspicious	0
2) ECG	Significant ST depression	2
	Nonspecific repolarization disturbance	1
	Normal	0
3) Age	≥ 65 year	2
	45-65 year	1
	< 45 year	0
4) Risk factors	≥ 3 risk factors or history of atherosclerotic disease	2

6		1 or 2 risk factors	1
7		No risk factors known	0
9	5) Troponin	>2x normal limit	2
11		1-2x normal limit	1
12		≤ normal limit	0

14 Low risk: the score of ≤3 AND troponin <99th percentile value

17 3. EDACS (16)

19	1) Age	score
21	18 – 45	+2
22	46 – 50	+4
24	51 – 55	+6
26	56 – 60	+8
28	61 – 65	+10
29	66 – 70	+12
31	71 – 75	+14
32	76 – 80	+16
34	81 – 85	+18
36	86 ≤	+20
37	2) Male sex	+6
39	3) Aged 18 – 50 years and either:	
41	a. known coronary artery disease	+4
42	b. ≥3 risk factors	
44	4) Symptom and signs	
46	Diaphoresis	+3
47	Radiates to arm or shoulder	+5
49	Pain occurred or worsened with inspiration	-4
51	Pain is reproduced by palpation	-6

52 Low risk: EDACS <16, AND no new ischemia on ECG, AND both 0 and 2 h troponin <99th percentile

4. T-MACS (17)

E) ECG ischemia

A) Worsening or crescendo angina

R) Right arm or shoulder pain

V) Vomiting

S) Sweating observed

H) Hypotension (systolic blood pressure < 100 mm Hg)

T) High-sensitivity troponin T concentration on arrival (ng/L)

$$\text{Probability} = 1 / (1 + e^{-(1.713E + 0.847A + 0.607R + 1.417V + 2.058S + 1.208H + 0.089T - 4.766)})$$

Low risk: probability <0.02

5. TRUST (35)

1) Modified Goldman risk score ≤ 1

a. Typical new-onset chest pain at rest

b. Pain the same as previous myocardial infarction

c. Pain not relieved by glyceryl trinitrate spray within 15 min

d. Pain lasting more than 60 min

e. Pain occurring with increasing frequency

f. Hypotension (systolic blood pressure < 100 mm Hg)

g. Acute shortness of breath

h. Pain within 6 weeks of a myocardial infarction or revascularization

2) Non-ischemic ECG

3) High-sensitivity troponin T concentration at presentation <14 ng/L

Low risk: all parameters, 1), 2), and 3) are satisfied

6. GRACE (10)

1) Age	score
≤ 39	0
40 – 49	18

1		
2		
3		
4		
5		
6	50 – 59	36
7	60 – 69	55
8	70 – 79	73
9	80 – 89	91
10	≥90	100
11		
12		
13		
14	2) History of congestive heart failure	24
15		
16	3) History of myocardial infarction	12
17		
18	4) Resting heart rate (beats/min)	
19	≤49.9	0
20		
21	50 – 69.9	3
22		
23	70 – 89.9	9
24		
25	90 – 109.9	14
26		
27	110 – 149.9	23
28		
29	150 – 199.9	35
30		
31	≥200	43
32		
33	5) Systolic blood pressure (mm Hg)	
34	≤79.9	24
35		
36	80 – 99.9	22
37		
38	100 – 119.9	18
39		
40	120 – 139.9	14
41		
42	140 – 159.9	10
43		
44	160 – 199.9	4
45		
46	≥200	0
47		
48	6) ST-segment depression	11
49		
50	7) Initial serum creatinine (mg/dl)	
51	≤0.39	1
52		
53	0.4 – 0.79	3
54		
55	0.8 – 1.19	5
56		
57	1.2 – 1.59	7
58		
59	1.6 – 1.99	9
60		

1		
2		
3		
4		
5		
6	2 – 3.99	15
7	≥4	20
8		
9	8) Elevated cardiac enzymes	15
10		
11	9) No in-hospital percutaneous coronary intervention	14
12		
13	Low risk: the score of ≤140 AND both 0 and 2 h troponin <99 th percentile	
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

BMJ Open

A comprehensive validation of very early rule-out strategies for non-ST-segment elevation myocardial infarction in emergency departments: protocol for a multicenter prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026985.R2
Article Type:	Protocol
Date Submitted by the Author:	06-Jun-2019
Complete List of Authors:	<p>Tada, Masafumi; Kyoto University, Graduate School of Medicine and School of Public Health</p> <p>Azuma, Hiroyuki; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Yamada, Naoki; Fukui University Hospital, Department of Emergency Medicine</p> <p>Kano, Ken-ichi; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Nagai, Hideya; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Maeda, Shigenobu; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Ishida, Hiroshi; Fukui Prefectural Hospital, Department of Emergency Medicine</p> <p>Aoyama, Takahiko; Fukui Prefectural Hospital, Cardiology, Vascular Center</p> <p>Okada, Ryota; Fukui University Hospital, Department of Emergency Medicine</p> <p>Kawano, Takahisa; Fukui University Hospital, Department of Emergency Medicine</p> <p>Kobuchi, Taketsune; Fukui University Hospital, Department of Emergency Medicine</p> <p>Uzui, Hiroyasu; Fukui University Hospital, Department of Cardiovascular Medicine</p> <p>Matano, Hideyuki; Fukui-ken Saiseikai Hospital, Department of Emergency Medicine</p> <p>Iwasaki, Hose; Fukui-ken Saiseikai Hospital, Department of Emergency Medicine</p> <p>Maeno, Koji; Fukui-ken Saiseikai Hospital, Department of Cardiology</p> <p>Shimada, Yoshimitsu; Japanese Red Cross Fukui Hospital, Department of Emergency Medicine</p> <p>Yoshida, Hiroyuki; Japanese Red Cross Fukui Hospital, Department of Cardiology</p> <p>Ando, Masaki; Nagoya City East Medical Center, Department of Emergency Medicine</p> <p>Murakami, Yoshimasa; Nagoya City East Medical Center, Department of Cardiovascular Medicine</p> <p>Iwakami, Naotsugu; National Cerebral and Cardiovascular Center,</p>

	Department of Research Promotion and Management Kishimoto, Sanae; Kyoto University, Graduate School of Medicine and School of Public Health Iwami, Taku ; Kyoto University , Department of Health Service Tada, Hiroshi; Fukui University Hospital, Department of Cardiovascular Medicine Chapman, Andrew; University of Edinburgh, British Heart Foundation Center for Cardiovascular Science Mills, Nicholas; University of Edinburgh, British Heart Foundation Center for Cardiovascular Science Hayashi, Hiroyuki; Fukui University Hospital, Department of Emergency Medicine Furukawa, Toshi; Kyoto University, Graduate School of Medicine and School of Public Health Watanabe, Norio; Kyoto University, Graduate School of Medicine and School of Public Health
Primary Subject Heading :	Emergency medicine
Secondary Subject Heading :	Cardiovascular medicine, Diagnostics
Keywords :	Myocardial infarction < CARDIOLOGY, troponin, ACCIDENT & EMERGENCY MEDICINE, Acute coronary syndrome

SCHOLARONE™
Manuscripts

1 **A comprehensive validation of very early rule-out strategies for non-ST-segment**
2 **elevation myocardial infarction in emergency departments: protocol for a multicenter**
3 **prospective cohort study**

4
5 Masafumi Tada,¹ Yoshida-konoecho, Sakyo-ku, Kyoto 606-8501 Japan

6 Correspondence to: tada.masafumi.76r@kyoto-u.jp. Phone: +81-75-753-9491

7
8 Hiroyuki Azuma,² Naoki Yamada,⁴ Ken-ichi Kano,² Hideya Nagai,² Shigenobu Maeda,²

9 Hiroshi Ishida,² Takahiko Aoyama,³ Ryota Okada,⁴ Takahisa Kawano,⁴ Taketsune

10 Kobuchi,⁴ Hiroyasu Uzui,⁵ Hideyuki Matano,⁶ Hose Iwasaki,⁶ Koji Maeno,⁷ Yoshimitsu

11 Shimada,⁸ Hiroyuki Yoshida,⁹ Masaki Ando,¹⁰ Yoshimasa Murakami,¹¹ Naotsugu

12 Iwakami,¹² Sanae Kishimoto,¹ Taku Iwami,¹³ Hiroshi Tada,⁵ Andrew R. Chapman,¹⁴

13 Nicholas L. Mills,¹⁴ Hiroyuki Hayashi,⁴ Toshiaki Furukawa,¹ Norio Watanabe¹

14
15 **Author affiliations**

16 ¹ Department of Health Promotion and Human Behavior, Kyoto University Graduate

17 School of Medicine, Yoshida-konoecho, Sakyo-ku, Kyoto 606-8501, Japan

18 ² Department of Emergency Medicine, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui 910-

19 8526, Japan

20 ³ Cardiology, Vascular Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui 910-8526,

21 Japan

22 ⁴ Department of Emergency Medicine, Fukui University Hospital, 23-3

23 Matsuokashimoaizuki, Eihei-cho, Yoshida-gun, Fukui 910-1193, Japan

24 ⁵ Department of Cardiovascular Medicine, Fukui University Hospital, 23-3

25 Matsuokashimoaizuki, Eihei-cho, Yoshida-gun, Fukui 910-1193, Japan

- 1 ⁶ Department of Emergency Medicine, Fukui-ken Saiseikai Hospital, 7-1 Funabashi,
2 Wadanaka-cho, Fukui 918-8503, Japan
- 3 ⁷ Department of Cardiology, Fukui-ken Saiseikai Hospital, 7-1 Funabashi, Wadanaka-cho,
4 Fukui 918-8503, Japan
- 5 ⁸ Department of Emergency Medicine, Japanese Red Cross Fukui Hospital, 2-4-1 Tsukimi,
6 Fukui 918-8501, Japan
- 7 ⁹ Department of Cardiology, Japanese Red Cross Fukui Hospital, 2-4-1 Tsukimi, Fukui
8 918-8501, Japan
- 9 ¹⁰ Department of Emergency Medicine, Nagoya East Medical Center, 1-2-23 Wakamizu,
10 Chikusa-ku, Nagoya 464-8547, Japan
- 11 ¹¹ Department of Cardiovascular Medicine, Nagoya East Medical Center, 1-2-23
12 Wakamizu, Chikusa-ku, Nagoya 464-8547, Japan
- 13 ¹² Department of Research Promotion and Management, National Cerebral and
14 Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan
- 15 ¹³ Department of Health Services, Kyoto University, Yoshida-Honmachi, Sakyo-ku, Kyoto,
16 606-8501, Japan
- 17 ¹⁴ British Heart Foundation Center for Cardiovascular Science and Usher Institute of
18 Population Health Sciences and Informatics, University of Edinburgh, Chancellors
19 Building, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, United Kingdom

20 **Word count:** 4313

21 **Keywords:** myocardial infarction, high sensitivity troponin, clinical impression, prediction
22 rule

23

1 **ABSTRACT**

2 **Introduction**

3 Recent advances in troponin sensitivity enabled early and accurate judgement of ruling-out
4 myocardial infarction, especially non-ST elevation myocardial infarction (NSTEMI) in
5 emergency departments (ED) with development of various prediction-rules and high-
6 sensitive-troponin-based strategies (hs-troponin). Reliance on clinical impression, however,
7 is still common, and it remains unknown which of these strategies is superior. Therefore,
8 our objective in this prospective cohort study is to comprehensively validate the diagnostic
9 accuracy of clinical impression-based strategies, prediction-rules, and hs-troponin-based
10 strategies for ruling-out NSTEMIs.

12 **Methods and analysis**

13 In total, 1500 consecutive adult patients with symptoms suggestive of acute coronary
14 syndrome will be prospectively recruited from five EDs in two tertiary-, two secondary-
15 level community hospitals, and one university hospital in Japan. The study has begun in
16 July 2018, and recruitment period will be about one year. A board-certified emergency
17 physician will complete standardized case report forms, and independently perform a
18 clinical impression-based risk estimation of NSTEMI. Index strategies to be compared will
19 include: the clinical impression-based strategy; prediction rules; and hs-troponin-based
20 strategies for the following types of troponin (Roche Elecsys hs-troponin T; Abbott
21 ARCHITECT hs-troponin I; Siemens ADVIA Centaur hs-troponin I; Siemens ADVIA
22 Centaur sensitive-troponin I). The reference standard will be the composite of type 1 MI
23 and cardiac death within 30 days after admission to the ED. Outcome measures will be
24 NPV, sensitivity and effectiveness, defined as the proportion of patients categorized as low

1 risk for NSTEMI. We will also evaluate inter-rater reliability of the clinical impression-
2 based risk estimation.

3 4 **Ethics and dissemination**

5 The study is approved by the Ethics Committees of the Kyoto University Graduate School
6 and Faculty of Medicine and of the five hospitals where we will recruit patients.

7 8 **ARTICLE SUMMARY**

9 **Strengths and limitations of this study**

- 10 ■ This is the first prospective study to compare clinical impression-based strategies,
11 prediction-rules and hs-troponin-based strategies for ruling-out NSTEMI in patients
12 with symptoms suggestive of acute coronary syndrome in ED.
- 13 ■ We will also evaluate the inter-rater reliability of the clinical impression-based risk
14 estimation and discuss the usefulness of the strategies considering both the diagnostic
15 accuracy and the inter-rater reliability.
- 16 ■ We will use three high-sensitive-troponin and one sensitive-troponin which are
17 currently widely available in order to increase the applicability of the results of our
18 study.
- 19 ■ A limitation of the study is that troponin will rarely be taken later than three hours
20 after presentation to ED and we follow-up patients mainly by telephone interview, and
21 therefore, we may miss some subsequent MIs, although it is very unlikely that patients
22 will have a MI and not reattend hospital.
- 23 ■ Because the study population is only from Japan, the generalizability of the results
24 might be limited, although the prevalence of MI varies largely among previous studies
25 and that of our study will be somewhere among them.

1

2 INTRODUCTION

3 Background

4 Because ruling-out non-ST elevation myocardial infarctions (NSTEMI) is often
5 challenging, the American College of Cardiology (ACC) / American Heart Association
6 (AHA) and European Society of Cardiology (ESC) 2007 guidelines mandate the serial
7 troponin tests over a period of 6 to 12 h after symptom onset or admission to the emergency
8 department (ED).(1, 2) This long period of observation is the principal reason for admitting
9 patients with symptoms that might be related to an myocardial infarction (MI) and is, in
10 fact, the most frequent reason for admission in ED in both the United Kingdom and the
11 United States.(3, 4) However, between 75% and 95% of patients presenting to the EDs with
12 symptoms suggestive of MI did not have MI.(5, 6) Therefore, earlier and safer strategies to
13 rule-out an MI in EDs, which would allow patients to be discharged directly from the ED,
14 have been in a great demand. It is generally accepted that the risk of MI and death within
15 30 days should be less than one to two percent to patients directly discharged from the ED.
16 (7, 8)

17
18 Recently, several high-sensitive-troponins (hs-troponin) have decreased the recommended
19 time for troponin monitoring for MI diagnosis to 3-6 h (2014 ACC/AHA guidelines (9)),
20 and further to 0-3 h (2015 ESC guidelines (10)). Furthermore, a large individual patient-
21 level data meta-analysis reported that when the initial troponin value was much lower than
22 the 99th percentile, the negative predictive value (NPV) was consistently >99% across the
23 included cohorts.(6) Therefore, the time frame of serial troponin monitoring could be
24 greatly shortened, or even made unnecessary, for certain populations. The population in

1 East Asia may be appropriate for very early 'ruling-out' strategies of MI since the incidence
2 of MI in East Asia, especially in Japan, is much lower than in Western countries.(11)

3
4 Although troponin is crucial for the accurate diagnosis of MI, the clinical history, physical
5 findings and electrocardiogram (ECG) are also essential. Several clinical decision-making
6 models have been developed for MI, including the clinical impression-based strategy,
7 prediction rules and the hs-troponin-based strategy. The clinical impression-based strategy
8 is a traditional approach where clinical gestalt is used to estimate risk based on the history
9 and physical findings, and review of the ECG and troponin. Although few reports are
10 available, this approach remains common in practice, especially in Japan. However, the
11 inter-rater reliability of the risk estimation for MI based on clinical impression has not been
12 comprehensively evaluated, and previous studies suggested that risk estimation for MI
13 varies greatly, depending on the physician's experience and background.(12, 13)

14
15 Prediction rules have been developed that consider clinical findings and troponin
16 monitoring in a structured way to determine the risk of an MI. Several prediction rules to
17 estimate the risk of an MI have been defined, including the TIMI,(14) HEART,(15)
18 EDACS,(16) and T-MACS(17) rules. Most of the newer prediction rules that have
19 incorporated hs-troponin have achieved an NPV of >99% and have been validated.(18-21)
20 Prediction rules, however, are not widely used, despite their excellent NPVs, partly because
21 they have not been compared against clinical impression-based strategies.(22)

22
23 There are several hs-troponin-based strategies that use only hs-troponin, such as the 0 and
24 1h algorithm,(23) the 0 and 2h algorithm(24) and the High-STEACS pathway.(25) These
25 strategies are simple, and they rely on a measurement of hs-troponin only, with

1 demonstrated NPVs of >99%. Hs-troponin assays have excellent precision at very low
2 concentrations with very few analytical false positives.(26) On the other hand, the clinical
3 history, physical findings, and ECG readings are sometimes not reliable, and different
4 physicians often have different interpretations.(13, 27) Although they are essential
5 components of a comprehensive clinical assessment, the first risk stratification might be
6 better to be based on something that is highly reliable, with subsequent risk stratification
7 performed using clinical judgement, especially in ED where physicians with differing
8 backgrounds and experience work. However, the cutoffs of troponin levels in these hs-
9 troponin strategies tend to be much lower than the 99th percentile and patient age, which
10 has previously been associated with an increase in troponin level,(28, 29) may affect the
11 proportion of patients to be ruled-out. As such, hs-troponin-based strategies may be less
12 efficient in highly aged populations, such as in Japan.

14 **Rationale for the study**

15 First, although many strategies to rule-out MI have been proposed, a comprehensive
16 prospective validation of the clinical impression-based strategies, prediction-rules and hs-
17 troponin-based strategies to rule-out MI has not been performed.

18
19 Second, although the use of serial troponin and the cutoffs below the 99th percentile of
20 troponin are recommended in Western countries, it has not yet been proven well in East
21 Asia, where the incidence of MI is low and reliance on the clinical impression-based
22 strategy is common.(11) Because serial troponin is not only time consuming, but requires
23 additional resources and medical expenses, there is a need, particularly in East Asia, to
24 evaluate the NPV of clinical impression-based strategies, combined with troponin levels
25 obtained at different time points, using the 99th percentile cutoff value.

1
2
3
4
5
6 1
7
8 2 Third, although many kinds of troponins are now available, the diagnostic accuracy and
9
10 3 cutoff are each troponin specific. Our proposed study will include the four types of troponin
11
12 4 that are currently widely available: Roche hs-troponin T; Abbott hs-troponin I; Siemens hs-
13
14 5 troponin I; Siemens sensitive-troponin I in order to increase the applicability of our results
15
16 6 to as many facilities as possible.
17
18 7

8 **Study objectives**

9 **1. Primary research objective**

10 Our primary objective is to compare the NPV, sensitivity and effectiveness (defined as the
11
12 11 proportion of patients categorized into low risk to all patients to whom a strategy was
13
14 12 applied) of the three clinical impression-based strategies with three time frames of troponin
15
16 13 monitoring: on arrival (0 h) only; 0 h and 1 h after; and 0 h and 2 h after, using the
17
18 14 composite outcome of cardiac death or the occurrence of a type 1 MI within 30 days of the
19
20 15 ED consultation.
21
22 16

17 **2. Secondary research objectives**

18 Our secondary research objectives are:

19 2.1. To validate and compare the NPV, sensitivity and effectiveness between clinical
20
21 20 impression-based strategies, prediction rules and hs-troponin-based strategies.

22 2.2. To evaluate the inter-rater reliability of the clinical impression-based strategy, in
23
24 22 estimating the risk estimation of an MI, when performed by board certified emergency
25
26 23 physicians and senior residents of emergency medicine, general internists, cardiologists,
27
28 24 junior residents, and nurses.
29
30 25

METHODS AND ANALYSIS

Setting

We will recruit patients from five EDs in two tertiary-level community hospitals (Fukui Prefectural Hospital, Nagoya East Medical Center), two secondary-level community hospitals (Fukui-ken Saiseikai Hospital, Japanese Red Cross Fukui Hospital) and one university hospital (Fukui University Hospital) in Japan. Because patient recruitment is slow, we are adding a number of hospitals. We have purposively selected hospitals which cover the majority of emergency cases in the rural as well as urban to suburban areas.

Inclusion criteria

1. Age ≥ 25 years
2. Have any one of the following symptoms suspected to be MI
 - Chest pain
 - Non-chest pain, including radiating pain, syncope, dyspnea, nausea / vomiting, and fatigue, and other symptoms which emergency physicians judge to need to rule out an MI
3. Presentation to the ED within 6 hours from symptom onset. We will set the threshold at six hours to focus on early presenters, the most difficult population to rule-out NSTEMI very early (30)
4. No apparent ST elevation on arrival
5. The use of both ECG and the troponin test, as deemed to be required by the ED physician

Exclusion criteria

1. Cardiopulmonary arrest on arrival

- 1 2. Non-cardiac terminal illness (expected survival less than six months)
- 2 3. Need for resuscitation (physiological shock, continuous oxygen administration)
- 3 4. Indication of emergency catheterization on arrival
- 4 5. Inability of the patient to provide consent
- 5 6. Previous inclusion in the study
- 6 7. Unable to contact for follow-up after 30 days
- 7 8. Unknown time of onset of symptoms
- 8 9. Apparent need to admit for a diagnosis other than acute coronary syndrome on arrival
- 9 10. Patients on maintenance dialysis
- 10 11. Judged as ineligible by an emergency physician

12 **Participants recruitment**

13 When an MI is suspected, an ECG will be obtained first, as per usual practice. If there is no
14 significant ST elevation, a board-certified emergency physician will assess the eligibility of
15 the patient for enrollment into the study. Because board-certified emergency physicians are
16 not regularly available at night or on weekends in three of the participating hospitals
17 (Fukui-ken Saiseikai Hospital; Japanese Red Cross Fukui Hospital; and Nagoya East
18 Medical Center), patients will only be recruited when board-certified emergency physicians
19 are working in these centers. In the other two facilities (Fukui Prefectural Hospital and
20 Fukui University Hospital), board-certified emergency physicians are available around the
21 clock and, therefore, patients will be recruited as they present to the EDs. We will review
22 the patient recruitment status regularly by checking clinical records of all patients who visit
23 emergency department in all hospitals to ensure representativeness and minimise spectrum
24 bias.

1 **Informed consent**

2 We will obtain written informed consent from all patients. Because MI is more common in
3 the elderly, it may be sometimes difficult to obtain informed consent from some patients
4 due to dementia. Because excluding these patients will impair the validity of the study, we
5 will seek to obtain consent from patient's authorized proxy in such cases. We will conduct
6 this study in accordance with the Declaration of Helsinki and its amendments. This study is
7 registered in the UMIN-CTR registry (UMIN 000029992).

9 **Clinical assessments**

10 The following assessments will be performed at each site using standardized case report
11 forms (CRF): history; physical examination; clinical impression-based risk estimation;
12 ECG; standard blood tests; ultrasonography; and troponin levels (using both in-house and
13 research troponin types). Clinical impression-based risk estimation for a NSTEMI will be
14 classified as low, intermediate or high for analysis. The certainty of each item of the
15 clinical history and ECG will be measured using a 4-point Likert scale. The inter-rater
16 reliability will be evaluated between a board-certified emergency physician and one of the
17 following medical staff: a board-certified emergency physician; an emergency medicine
18 resident; a junior resident; a general practitioner; a cardiologist; or a nurse for 300
19 consecutive patients enrolled into the study. The following variables will be included for
20 inter-rater reliability: clinical impression-based risk estimation; each item of the clinical
21 history; ECG; ultrasonography. Assessors will not be provided with results of the troponin
22 levels, ultrasonography examination or the previous assessment performed by another
23 emergency physician or cardiologist before completion of the CRF. Because it will
24 occasionally be difficult to mask this information, we will report the masking status.
25 Management of patients will be left to the discretion of treating emergency physicians and

1 cardiologists, based on the results of in-house troponin measurements in each hospital. The
 2 indication of early invasive strategy will follow current guidelines. (9, 10, 31) We will
 3 check all case report forms immediately after we receive them from hospitals. If there are
 4 some missing values, we will ask co-researchers and make efforts to retrieve them as much
 5 as possible.

7 **Troponin**

8 We will evaluate the following four types of troponin, three high-sensitive and one
 9 sensitive. The 99th percentile and the limit of detection (LoD) values for the four types of
 10 troponin are summarized in Table 1. We will use sex-specific 99th percentile values for
 11 three types of hs-troponin in sensitivity analyses. We will collect blood samples in serum
 12 tubes for troponin levels on arrival (0 h); and at one hour (1 h), two hours (2 h), and three
 13 hours (3 h) after the first blood draw. After centrifugation, serum samples will be stored at
 14 less than -20°C until measured in each manufacturer's laboratory in a blinded fashion.

16 Table 1 The 99th percentile and LoD values for four types of troponin

Troponin	99 th percentile (ng/L)	LoD (ng/L)
Roche Elecsys hs-troponin T (general)	14.0	3.0
Roche Elecsys hs-troponin T (male)	15.5	
Roche Elecsys hs-troponin T (female)	9.0	
Abbott ARCHITECT hs-troponin I (general)	26.2	1.9
Abbott ARCHITECT hs-troponin I (male)	34.2	
Abbott ARCHITECT hs-troponin I (female)	15.6	
Siemens ADVIA Centaur hs-troponin I (general)	46.5	2.2

Siemens ADVIA Centaur hs-troponin I (male)	58.1	
Siemens ADVIA Centaur hs-troponin I (female)	39.6	
Siemens ADVIA Centaur sensitive-troponin I	40.0	6.0

LoD indicates limit of detection

Index tests

We will evaluate the three types of decision-making models to rule-out MI: the clinical impression-based strategies, prediction rules, and hs-troponin-based strategies. An author (MT) searched PubMed (December 2017) for prediction rules and hs-based strategies to rule-out MI in ED. We also consulted reviews on this topic to identify suitable decision-making models. Among identified prediction-rules and hs-troponin-based strategies, we selected those which were validated and showed an NPV of >99%, using any types of troponin. We will include strategies with troponin taken up to two hours apart from the first one. Because it generally takes about one hour to take the first blood sample, we will include strategies with troponin taken up to three hours from presentation. All the intervals of troponin sampling we showed below are the time from the first blood draw. Each troponin will be adapted for each strategy, as needed. We will define the troponin cutoff at the 99th percentile value, except for hs-troponin-based strategies, and the T-MACS. The troponin cutoffs for hs-troponin-based strategies are specific for each type of troponin, as detailed below. Troponin values will be incorporated as a continuous variable in the T-MACS. We will adopt cutoffs for each strategy in accordance with the original publication for each strategy. The details of each prediction rule are shown in the online supplementary appendix. All the index tests will be applied to a patient using prospectively collected clinical information after we complete patient recruitment.

1
2
3
4
5
6 1 The clinical impression-based strategies
7

8 2 1. The 0 h model
9

- 10 3 1) Clinical impression-based risk estimation for history and physical findings is not high
11 risk
12 4
13
14 5 2) No new ischemic findings on ECG
15
16 6 3) Troponin taken on arrival is below the 99th percentile
17
18 7

19
20 8 2. The 0 h and 1 h model
21

- 22 9 1) Clinical impression-based risk estimation for history and physical findings is not high
23 risk
24 10
25
26 11 2) No new ischemic findings on ECG
27
28 12 3) Troponin taken on arrival and at 1 h apart are both below the 99th percentile
29
30 13

31
32 14 3. The 0 h and 2 h model
33

- 34 15 1) Clinical impression-based risk estimation for history and physical findings is not high
35 risk
36 16
37
38 17 2) No new ischemic findings on ECG
39
40 18 3) Troponin taken on arrival and at 2 h apart are both below the 99th percentile
41
42 19

43
44 20 We will evaluate the clinical impression-based risk estimation for history and physical
45 findings based on the AHA/ACC guideline(32) and a systematic review.(33) We define the
46 21 new ischemic findings on ECG as an ST depression and negative T wave not known to be
47 22 old. An ST depression is defined by a depression of 0.05mV or more at J point in two or
48 23 more contiguous leads. A negative T wave is defined by T wave inversions of 0.1mV or
49
50
51
52 24
53
54
55
56
57
58
59
60

1 more in two or more contiguous leads. If all three components of each model are satisfied,
 2 we regard a patient as being at low risk for an MI.

3 4 Prediction rules

5 1. TIMI + 2 h troponin(34)

6 Components: age, coronary risk factors, use of aspirin, significant coronary stenosis,
 7 severe angina, ECG, and troponin (at 0 and 2 h)

8 Cutoff: we will define the score of 0 as a low risk for MI

9 2. HEART(15)

10 Components: history, ECG, age, risk factors, and troponin

11 Cutoff: we will define the score of 0-3 and negative troponin as a low risk for MI

12 3. EDACS(16)

13 Components: age, sex, coronary artery disease or risk factors, symptoms, ECG, and
 14 troponin (at 0 and 2 h)

15 Cutoff: we will define low risk when all three conditions are satisfied, namely: a score <
 16 16; no new ischemia on ECG; and negative troponin at 0 and 2 h

17 4. T-MACS(17)

18 Components: (E) ECG ischemia, (A) Worsening or crescendo angina, (R) Right arm or shoulder pain,
 19 (V) Vomiting, (S) Sweating observed, (H) Hypotension (systolic blood pressure < 100 mm Hg)
 20 (T) High-sensitivity troponin T concentration on arrival (ng/L)

21 Probability = $1 / (1 + e^{-(1.713E + 0.847A + 0.607R + 1.417V + 2.058S + 1.208H + 0.089T - 4.766)})$

22 Cutoff: we will define low risk if the probability is <0.02

23 5. TRUST(35)

24 Components: typical new-onset chest pain at rest, pain the same as previous MI, pain not
 25 relieved by glyceryl trinitrate within 15 min, pain lasting more than 60 min,

1 pain occurring with increasing frequency, hypotension, acute shortness of breath,
2 pain within 6 weeks of an MI or revascularization, ECG, hs-troponin (at 0 h)
3 Cutoff: we will define low risk when all three conditions are satisfied: the score of 0 or 1,
4 non-ischemic ECG, and negative troponin

5 6. GRACE(10)

6 Components: age, history of congestive heart failure, history of myocardial infarction,
7 resting heart rate, systolic blood pressure, ST-segment depression, initial serum
8 creatinine, elevated cardiac enzymes, no in-hospital percutaneous coronary
9 intervention

10 Cutoff: we will define the score less than 140 AND negative troponin at 0 and 2 h

12 Hs-troponin-based strategies

13 Hs-troponin-based strategies are comprised of hs-troponin only, with cutoff values being
14 troponin specific, as shown below for the five algorithms that will be used in the study. If a
15 troponin value is below the cutoff values of each strategy, we regard a patient as being at
16 low risk for an MI. In the High-STEACS pathway, a second troponin measurement is
17 obtained three hours from presentation to the ED.(25) Because there is often a delay of up
18 to one hour for the first blood sample, the average time between the first and second
19 troponin measurement is two hours, and therefore, we include the High-STEACS pathway
20 without modification.

22 1. The 0 h algorithm(36, 37)

23 Roche hs-troponin T: 0 h <5 ng/L(*1)

24 Abbott hs-troponin I: 0 h <2 ng/L(*2)

25 Siemens hs-troponin I: 0 h <3 ng/L(*3)

- 1 Siemens sensitive-troponin I: 0 h <0.5 ng/L^(*4)
- 2
- 3 2. The 1 h algorithm(23, 37-39)
- 4 Roche hs-troponin T: 0 h <12 ng/L AND Δ 0-1 h <3 ng/L^(*5)
- 5 Abbott hs-troponin I: 0 h <5 ng/L AND Δ 0-1 h <2 ng/L^(*6)
- 6 Siemens hs-troponin I: 0 h <6 ng/L AND Δ 0-1 h <3 ng/L^(*7)
- 7 Siemens sensitive-troponin I: 0 h <10 ng/L AND Δ 0-1 h <4 ng/L^(*8)
- 8
- 9 3. The 2 h algorithm(24, 39, 40)
- 10 Roche hs-troponin T: 0 and 2 h <14 ng/L AND Δ 0-2 h <4 ng/L
- 11 Abbott hs-troponin I: 0 and 2 h <6 ng/L AND Δ 0-2 h <2 ng/L
- 12 Siemens sensitive-troponin I: 0 and 2 h <10 ng/L
- 13
- 14 4. The 0 and 1h algorithm(10, 37)
- 15 Roche hs-troponin T: *1 OR *5
- 16 Abbott hs-troponin I: *2 OR *6
- 17 Siemens hs-troponin I: *3 OR *7
- 18 Siemens sensitive-troponin I: *4 OR *8
- 19
- 20 5. The High-STEACS pathway (only for Abbott hs-troponin I at the moment) (25)
- 21 If hs-troponin I at 0 h <5 ng/L AND symptom onset \geq 2 h, AMI is ruled out.
- 22 If $5 \leq$ hs-troponin I at 0 h \leq 26.2 ng/L OR symptom onset <2 h, hs-troponin I at 2 h is
- 23 required. If Δ 0-2 h hs-troponin I <3ng/L AND hs-troponin I at 3 h \leq 26.2 ng/L, AMI is
- 24 ruled out.
- 25

1 **Reference standard**

2 **Final diagnosis adjudication**

3 Two cardiologists of each facility will independently adjudicate the final diagnosis based
4 on the results of the follow-up telephone interview and all available clinical information
5 obtained 30 days or more after the admission to the ED: each item of the clinical history;
6 physical examination; laboratory tests (both in-house troponin and hs-troponin T taken at 0
7 and 3 h); ECG; ultrasonography; cardiac stress test; radiological test; and coronary
8 angiography. Disagreements will be resolved through discussions between the two
9 cardiologists. If they are unable to reach consensus, a third cardiologist will be consulted.
10 All cardiologists will be masked from the results of index tests and the research hs-troponin
11 obtained at 1 and 2 h.

12 The diagnosis of MI will be made in accordance with the forth universal definition of
13 myocardial infarction,(41) and classified as type 1, type 2, type 4b, and myocardial injury.
14 Briefly, an MI will be diagnosed if there is a significant rise and/or fall of troponin, with at
15 least one value above the 99th percentile, in a clinical setting consistent with acute
16 myocardial ischemia. We will adjudicate final diagnosis with each of hs-troponin assays
17 (Roche hs-troponin T, Abbott hs-troponin I, and Siemens hs-troponin I). We will use the
18 same hs-troponin to adjudicate the final diagnosis as that used for index tests to avoid
19 unequal incorporation bias. We will define a significant rise and/or fall for three hours as 6
20 ng/L for Roche hs-troponin T; the relative increase of >50% of the respective 99th
21 percentile value if the initial troponin value is equal or less than the 99th percentile value,
22 and the relative increase of >20% of the initial value if the initial troponin values is greater
23 than the 99th percentile value for Abbott hs-troponin I and Siemens hs-troponin I.(23, 26)
24 Type 1 MI is defined as myocardial necrosis with symptoms suggestive of MI or test results
25 which prove myocardial ischemia. Type 2 MI is defined as myocardial necrosis, with a

1 condition other than coronary artery disease, which contributes to an oxygen supply-
2 demand imbalance (e.g. coronary artery spasm; tachyarrhythmia; respiratory failure; or
3 anemia). Type 4b is an MI associated with stent thrombosis.

4 5 **Clinical outcomes**

6 The primary clinical outcome will be the composite of type 1 MI and cardiac death within
7 30 days of the ED admission. We will add type 2 and 4b MI to the primary clinical
8 outcome as a sensitivity analysis, because it will be occasionally difficult to differentiate
9 type 1 MI and other types of MI. If patients consult an ED or cardiac service in the study
10 facility again, emergency physicians or cardiologists will ask patients if they have had an
11 MI or if they have undergone any cardiac tests or revascularization in other hospitals.
12 Because not all patients can be expected to consult a study facility again, research staffs
13 will conduct structured telephone follow-up interview with all patients enrolled into the
14 study, 30 days after the ED admission. At 30 days, if patients have either consulted a study
15 facility again or if sufficient clinical information is available, we will include only type 1
16 MI as the primary clinical outcome. Whilst for patients who do not consult a study facility
17 again and, therefore, only information from the telephone follow-up is for clinical
18 outcomes, it will be difficult to differentiate type 1 MI from other types of MI. In these
19 cases, we will include all MI types (1, 2 and 4b) as the primary clinical outcome. Similarly,
20 the adjudication of a cause of death might be difficult in some patients. In this case, we will
21 include an unknown cause of death into our primary outcome. Patients who do not consult a
22 study facility again and could not be reached for the telephone follow-up interview will be
23 excluded from the primary and secondary research objectives.

24 25 **Sample size calculation**

1 Assuming that the event rate of the primary clinical outcome is 5 to 10%,(6, 11) with a
2 sensitivity and specificity of the clinical impression-based strategies of 95% and 55%,
3 respectively,(42) 1500 patients will need to be enrolled into the study if the lower limit of
4 95% CI of the NPV is to surpass 98%.

6 **Data analysis**

7 **Missing values**

8 For missing values in clinical assessments, we will use the multiple imputation technique to
9 minimise bias and preserve study power. We will also perform complete case analysis as a
10 sensitivity analysis.

12 **Primary research objective**

13 We will describe the NPV, sensitivity and effectiveness of the three clinical impression-
14 based strategies, using the 95%CI for each troponin. We will also calculate the specificity,
15 positive predictive value, and area under the receiver operating characteristic curve (AUC)
16 for each strategy. We will derive a generalized score statistic to compare NPV, and use the
17 McNemar test to compare sensitivity and effectiveness. We will regard a strategy as being
18 clinically useful if the point estimate for NPV is $\geq 99\%$. If the point estimate for NPV is
19 $\geq 99\%$, we will regard a strategy with shorter observational period as superior.

21 **Secondary research objective 1**

22 We will describe the NPV, sensitivity, effectiveness, AUC for the clinical impression-based
23 strategies, prediction rules, and hs-troponin-based strategies for each troponin. If the point
24 estimate for NPV is $\geq 99\%$, we will regard a strategy with higher effectiveness and / or
25 shorter observational period as superior.

1

2 **Secondary research objective 2**

3 Reliability will be evaluated for 300 consecutive patients. We will use Cohen's weighted
4 Kappa-statistic and the boot-strap method, with 1000 replications, to determine the 95% CI
5 boundaries of reliability.

6

7 **Sensitivity analysis**

8 A sensitivity analysis will be performed including type 2 and 4b MI to the primary clinical
9 outcome. We will compare the NPV, sensitivity and effectiveness of the index tests
10 between subgroups stratified by: time from symptom onset to hospital arrival; the clinical
11 impression-based risk estimation; past history of ischemic heart disease or
12 revascularization; age; sex; and presence of chest pain considering its certainty. We will
13 define the cutoff of the clinical impression-based risk estimation as neither moderate nor
14 high. We also perform analyses by changing the cutoffs of other strategies. We will
15 combine the hs-troponin-based strategies with clinical impression-based risk estimation
16 and/or ECG, and evaluate the NPV, sensitivity, and effectiveness. We will use each of
17 Roche Elecsys hs-troponin T; Siemens ADVIA Centaur hs-troponin I; and Siemens
18 ADVIA Centaur sensitive-troponin I for the adjudication of MI. We will use sex-specific
19 99th percentiles of three types of hs-troponin for the index tests. We will perform complete
20 case analysis for primary and secondary research objectives.

21

22 **Ethics and dissemination**

23 This study is approved by the Ethics Committees of the Kyoto University Graduate School
24 and Faculty of Medicine (R1380, 27 February 2018) and the five hospitals where we will
25 recruit patients. We will disseminate the results of the study through peer-reviewed journals

1 and conference presentations. For the study participants, we will disseminate the brief
2 summary of the results of the study to all the EDs of study hospitals.

3 **Patient and public involvement**

4 No patients were asked for input in the creation of this article.

5 **Summary**

6 Along with the advance in troponin monitoring, the early management of MI suspected
7 patients is markedly changing. Though many troponins are available now, diagnostic
8 accuracy and cutoff values are specific for each type of troponin. Although many
9 prediction-rules and hs-troponin-based strategies have been published, it is still unknown if
10 these algorithms are superior to clinical impression-based strategies. The study will be the
11 first prospective study to compare clinical impression-based strategies, using four different
12 types of troponin that are commonly used to estimate the risk of an MI with prediction-
13 rules and hs-troponin-based strategies. We will also evaluate the inter-rater reliability of the
14 clinical impression-based risk estimation, and discuss the usefulness of these strategies,
15 considering both the diagnostic accuracy and the inter-rater reliability.

16 **Acknowledgments**

17 The authors sincerely thank the patients who are participating in the study. The authors
18 warmly thank emergency physicians, S. Tanizaki, M. Sera, M. Hayashi, T. Nakanishi, H.
19 Watanabe, and J. Tanaka in Fukui prefectural hospital; T. Kimura, H. Morita, T.
20 Yamanaka, T. Hamada, H. Tsuji, Y. Kuwabara, Y. Kamikawa in Fukui university hospital;
21 M. Inagaki, T. Miura, T. Ohno in Nagoya east medical center. The authors would like to
22 thank cardiologists, S. Fujino, M. Yamaguchi, Y. Noji, H. Kato, R. Yamamura, N. Ukawa,
23
24
25

1 Y. Takahashi in Fukui prefectural hospital; S. Miyazaki, K. Ishida, K. Kaseno, K.
2 Hasegawa, T. Morishita, Y. Fukuoka, H. Ikeda, N. Tama, Y. Shiomi, J. Yamaguchi, D.
3 Aoyama, T. Aiki, E. Ishikawa, M. Mukai, A. Matsui, K. Miyahara in Fukui university
4 hospital; H. Takemori, K. Ohkura, M. Hirazawa, S. Ohkura, H. Tsuneyama in Fukui-ken
5 Saiseikai hospital; T. Akiyoshi, K. Sarazawa, K. Sakakibara, J. Yamaguchi, T Kataoka in
6 Japanese red cross Fukui hospital; T. Saeki, N. Tamai, S. Yamashita, T. Yoshida, T.
7 Sekimoto, K. Hachiya, T. Hasuo, T. Hashimoto, T. Noda in Nagoya east medical center.
8 The authors also thank general physicians, residents, nurses, and clinical technologists of
9 the five study hospitals for their voluntary co-operation. The authors acknowledge clinical
10 laboratory technologists of the five study hospitals for blood sample handling; and the
11 Roche and T. Kikuchi, the Abbott and S. Sugawa, and the Siemens and T. Yokoyama for
12 biomarker measurement including troponin. The authors also appreciate K. Yamamoto and
13 the Union Think for offering an optical character recognition program to incorporate data
14 of paper CRF into REDCap (version 8.1.17; Nashville, TN) electronic data capturing
15 system.

17 **Author contributions**

18 MT, NW wrote the first draft. All other authors, HA, NY, KK, HN, SM, HI, TA, RO, TK,
19 TK, HU, HT, HM, HI, KM, YS, HY, MA, YM, NI, SK, TI, HT, AC, NM, HH and TF
20 contributed to the conception and design of the study. All the authors read and approved the
21 final manuscript.

23 **Funding**

24 The study is supported by grants from Nakatani Foundation (Tokyo, Japan), and from
25 Radiometer (Tokyo, Japan).

1

2 **Competing interests**

3 MT received non-financial support from Roche, Abbott, and Siemens during the conduct of
4 the study; personal fees from Japan Medical Journal, outside the submitted work. ARC has
5 received honoraria from Abbott Diagnostics and AstraZeneca. NLM has received honoraria
6 and consultancy from Abbott Diagnostics, Roche Diagnostics and Singulex. TF reports
7 personal fees from Meiji Seika, grants and personal fees from MSD, personal fees from
8 Pfizer, outside the submitted work. NW has received research funds from the Japanese
9 Ministry of Health Labor and Welfare, the Japanese Ministry of Education, Science, and
10 Technology and National Center of Neurology and Psychiatry, Intramural Research Grant
11 for Neurological and Psychiatric Disorders. He has also received royalties from Sogensha
12 and Akatsuki. All other authors report no conflicts.

13

14 **REFERENCES**

- 15 1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the
16 management of patients with unstable angina/non ST-elevation myocardial infarction: a
17 report of the American College of Cardiology/American Heart Association Task Force on
18 Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the
19 Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction):
20 developed in collaboration with the American College of Emergency Physicians, the
21 Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic
22 Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary
23 Rehabilitation and the Society for Academic Emergency Medicine. *Circulation*.
24 2007;116(7):e148-304.
- 25 2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and
26 treatment of non-ST-segment elevation acute coronary syndromes. *Eur Heart J*.
27 2007;28(13):1598-660.

- 1 3. Niska R, Bhuiya F, Xu J. National Hospital Ambulatory Medical Care Survey:
2 2007 emergency department summary. *Natl Health Stat Report*. 2010(26):1-31.
- 3 4. The Health and Social Care Information Centre. Hospital Episode Statistics,
4 Admitted Patient Care—England, 2013-14: Primary diagnosis, 3 characters table. URL:
5 [https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-](https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/hospital-episode-statistics-admitted-patient-care-england-2013-14#resources)
6 [patient-care-activity/hospital-episode-statistics-admitted-patient-care-england-2013-](https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/hospital-episode-statistics-admitted-patient-care-england-2013-14#resources)
7 [14#resources](https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/hospital-episode-statistics-admitted-patient-care-england-2013-14#resources) Date of access: Jan. 30 2019
- 8 5. Hollander JE, Than M, Mueller C. State-of-the-Art Evaluation of Emergency
9 Department Patients Presenting With Potential Acute Coronary Syndromes. *Circulation*.
10 2016;134(7):547-64.
- 11 6. Chapman AR, Lee KK, McAllister DA, et al. Association of High-Sensitivity
12 Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected
13 Acute Coronary Syndrome. *JAMA*. 2017;318(19):1913-24.
- 14 7. Miller C. Evaluation of patients with chest pain at low or intermediate risk for
15 acute coronary syndrome. Up To Date. URL:
16 [https://www.uptodate.com/contents/evaluation-of-patients-with-chest-pain-at-low-or-](https://www.uptodate.com/contents/evaluation-of-patients-with-chest-pain-at-low-or-intermediate-risk-for-acute-coronary-syndrome?search=Evaluation%20of%20patients%20with%20chest%20pain%20at%20low%20or%20intermediate%20risk%20for%20acute%20coronary%20syndrome.&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)
17 [intermediate-risk-for-acute-coronary-](https://www.uptodate.com/contents/evaluation-of-patients-with-chest-pain-at-low-or-intermediate-risk-for-acute-coronary-syndrome?search=Evaluation%20of%20patients%20with%20chest%20pain%20at%20low%20or%20intermediate%20risk%20for%20acute%20coronary%20syndrome.&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)
18 [syndrome?search=Evaluation%20of%20patients%20with%20chest%20pain%20at%20low](https://www.uptodate.com/contents/evaluation-of-patients-with-chest-pain-at-low-or-intermediate-risk-for-acute-coronary-syndrome?search=Evaluation%20of%20patients%20with%20chest%20pain%20at%20low%20or%20intermediate%20risk%20for%20acute%20coronary%20syndrome.&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)
19 [%20or%20intermediate%20risk%20for%20acute%20coronary%20syndrome.&source=sear](https://www.uptodate.com/contents/evaluation-of-patients-with-chest-pain-at-low-or-intermediate-risk-for-acute-coronary-syndrome?search=Evaluation%20of%20patients%20with%20chest%20pain%20at%20low%20or%20intermediate%20risk%20for%20acute%20coronary%20syndrome.&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1)
20 [ch_result&selectedTitle=1~150&usage_type=default&display_rank=1](https://www.uptodate.com/contents/evaluation-of-patients-with-chest-pain-at-low-or-intermediate-risk-for-acute-coronary-syndrome?search=Evaluation%20of%20patients%20with%20chest%20pain%20at%20low%20or%20intermediate%20risk%20for%20acute%20coronary%20syndrome.&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1) Date of access: Jan.
21 30 2019
- 22 8. Mahler SA, Miller CD, Hollander JE, et al. Identifying patients for early
23 discharge: performance of decision rules among patients with acute chest pain. *Int J*
24 *Cardiol*. 2013;168(2):795-802.
- 25 9. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for
26 the management of patients with non-ST-elevation acute coronary syndromes: a report of
27 the American College of Cardiology/American Heart Association Task Force on Practice
28 Guidelines. *Circulation*. 2014;130(25):e344-426.
- 29 10. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of
30 acute coronary syndromes in patients presenting without persistent ST-segment elevation:

- 1
2
3
4
5
6 1 Task Force for the Management of Acute Coronary Syndromes in Patients Presenting
7 without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
8 *Eur Heart J.* 2016;37(3):267-315.
- 9
10
11 4 11. Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors
12 in Asia: a selected review. *Circulation.* 2008;118(25):2702-9.
- 13
14 6 12. Hess EP, Brison RJ, Perry JJ, et al. Development of a clinical prediction rule for
15 30-day cardiac events in emergency department patients with chest pain and possible acute
16 coronary syndrome. *Ann Emerg Med.* 2012;59(2):115-25 e1.
- 17
18 8
19 9 13. Wu WK, Yiadom MY, Collins SP, et al. Documentation of HEART score
20 discordance between emergency physician and cardiologist evaluations of ED patients with
21 chest pain. *Am J Emerg Med.* 2017;35(1):132-5.
- 22
23 11
24 12 14. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable
25 angina/non-ST elevation MI: A method for prognostication and therapeutic decision
26 making. *JAMA.* 2000;284(7):835-42.
- 27
28 14
29 15 15. Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the
30 HEART score. Netherlands heart journal : *Neth Heart J.* 2008;16(6):191-6.
- 31
32 17 16. Than M, Flaws D, Sanders S, et al. Development and validation of the
33 Emergency Department Assessment of Chest pain Score and 2 h accelerated diagnostic
34 protocol. *Emerg Med Australas.* 2014;26(1):34-44.
- 35
36 19
37 20 17. Body R, Carlton E, Sperrin M, et al. Troponin-only Manchester Acute Coronary
38 Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation
39 in three cohorts. *Emerg Med J.* 2017;34(6):349-56.
- 40
41 22
42 23 18. Cullen L, Mueller C, Parsonage WA, et al. Validation of high-sensitivity troponin
43 I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department
44 patients with possible acute coronary syndrome. *J Am Coll Cardiol.* 2013;62(14):1242-9.
- 45
46 25
47 26 19. Meller B, Cullen L, Parsonage WA, et al. Accelerated diagnostic protocol using
48 high-sensitivity cardiac troponin T in acute chest pain patients. *Int J Cardiol.*
49 2015;184:208-15.
- 50
51 28
52 29 20. McCord J, Cabrera R, Lindahl B, et al. Prognostic Utility of a Modified HEART
53 Score in Chest Pain Patients in the Emergency Department. *Circ Cardiovasc Qual*
- 54
55
56
57
58
59
60

- 1 *Outcomes*. 2017;10(2).
- 2 21. Carlton EW, Khattab A, Greaves K. Identifying Patients Suitable for Discharge
3 After a Single-Presentation High-Sensitivity Troponin Result: A Comparison of Five
4 Established Risk Scores and Two High-Sensitivity Assays. *Ann Emerg Med*.
5 2015;66(6):635-45 e1.
- 6 22. Adams ST, Leveson SH. Clinical prediction rules. *BMJ*. 2012;344:d8312.
- 7 23. Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute
8 myocardial infarction using high-sensitivity cardiac troponin T. *Arch Intern Med*.
9 2012;172(16):1211-8.
- 10 24. Reichlin T, Cullen L, Parsonage WA, et al. Two-hour algorithm for triage toward
11 rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin
12 T. *Am J Med*. 2015;128(4):369-79 e4.
- 13 25. Chapman AR, Anand A, Boeddinghaus J, et al. Comparison of the Efficacy and
14 Safety of Early Rule-Out Pathways for Acute Myocardial Infarction. *Circulation*.
15 2017;135(17):1586-96.
- 16 26. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac
17 troponins in acute cardiac care. *Eur Heart J*. 2012;33(18):2252-7.
- 18 27. Body R, Carley S, Wibberley C, et al. The value of symptoms and signs in the
19 emergent diagnosis of acute coronary syndromes. *Resuscitation*. 2010;81(3):281-6.
- 20 28. Riedlinger D, Mockel M, Muller C, et al. High-sensitivity cardiac troponin T for
21 diagnosis of NSTEMI in the elderly emergency department patient: a clinical cohort study.
22 *Biomarkers*. 2018;23(6):551-7.
- 23 29. Welsh P, Preiss D, Shah ASV, et al. Comparison Between High-Sensitivity
24 Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. *Clin*
25 *Chem*. 2018;64(11):1607-1616.
- 26 30. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial
27 infarction with sensitive cardiac troponin assays. *N Engl J Med*. 2009;361(9):858-67.
- 28 31. Kimura T, Issiki T, Ohno T, et al. Guidelines for Management of Acute Coronary
29 Syndrome without Persistent ST Segment Elevation (JCS 2012). URL: [http://www.j-](http://www.j-circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf)
30 [circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf](http://www.j-circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf) Date of access: Jan. 30 2019

- 1
2
3
4
5
6 1 32. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the
7 2 management of patients with unstable angina/non-ST-Elevation myocardial infarction: a
8 3 report of the American College of Cardiology/American Heart Association Task Force on
9 4 Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the
10 5 Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction)
11 6 developed in collaboration with the American College of Emergency Physicians, the
12 7 Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic
13 8 Surgeons endorsed by the American Association of Cardiovascular and Pulmonary
14 9 Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol.*
15 10 2007;50(7):e1-e157.
16 11 33. Fanaroff AC, Rymer JA, Goldstein SA, et al. Does This Patient With Chest Pain
17 12 Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review.
18 13 *JAMA.* 2015;314(18):1955-65.
19 14 34. Than M, Cullen L, Aldous S, et al. 2-Hour accelerated diagnostic protocol to
20 15 assess patients with chest pain symptoms using contemporary troponins as the only
21 16 biomarker: the ADAPT trial. *J Am Coll Cardiol.* 2012;59(23):2091-8.
22 17 35. Carlton EW, Cullen L, Than M, et al. A novel diagnostic protocol to identify
23 18 patients suitable for discharge after a single high-sensitivity troponin. *Heart.*
24 19 2015;101(13):1041-6.
25 20 36. Rubini Gimenez M, Hoeller R, Reichlin T, et al. Rapid rule out of acute
26 21 myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. *Int J*
27 22 *Cardiol.* 2013;168(4):3896-901.
28 23 37. Boeddinghaus J, Twerenbold R, Nestelberger T, et al. Clinical Validation of a
29 24 Novel High-Sensitivity Cardiac Troponin I Assay for Early Diagnosis of Acute Myocardial
30 25 Infarction. *Clin Chem.* 2018;64(9):1347-1360.
31 26 38. Rubini Gimenez M, Twerenbold R, Jaeger C, et al. One-hour rule-in and rule-out
32 27 of acute myocardial infarction using high-sensitivity cardiac troponin I. *Am J Med.*
33 28 2015;128(8):861-70 e4.
34 29 39. Druey S, Wildi K, Twerenbold R, et al. Early rule-out and rule-in of myocardial
35 30 infarction using sensitive cardiac Troponin I. *Int J Cardiol.* 2015;195:163-70.

- 1
2
3
4
5
6 1 40. Boeddinghaus J, Reichlin T, Cullen L, et al. Two-Hour Algorithm for Triage
7 toward Rule-Out and Rule-In of Acute Myocardial Infarction by Use of High-Sensitivity
8 Cardiac Troponin I. *Clin Chem*. 2016;62(3):494-504.
9
10 41. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial
11 infarction (2018). *Eur Heart J*. 2019;40(3):237-269.
12
13 42. Body R, Cook G, Burrows G, et al. Can emergency physicians 'rule in' and 'rule
14 out' acute myocardial infarction with clinical judgement? *Emerg Med J*. 2014;31(11):872-6.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary appendix

The components of prediction rules**1. TIMI + 2 h troponin (34)**

- 1) Troponin level at 0 and 2 h below 99th percentile value
- 2) No new ischemic changes on the initial ECG
- 3) TIMI score = 0 (all items below have to be negative)
 - a. Age ≥ 65 years
 - b. Three or more risk factors for coronary artery disease
(family history of coronary artery disease, hypertension, hypercholesterolaemia, diabetes, or being in a current smoker)
 - c. Use of aspirin in the past 7 days
 - d. Significant coronary stenosis (previous coronary stenosis $\geq 50\%$)
 - e. Severe angina (≥ 2 angina events in past 24 h or persistent discomfort)
 - f. ST-segment deviation of ≥ 0.05 mV on first ECG
 - g. Increased troponin

Low risk: all parameters, 1), 2), and 3) are satisfied

2. HEART (15)

		score
1) History	Highly suspicious	2
	Moderately suspicious	1
	Slightly suspicious	0
2) ECG	Significant ST depression	2
	Nonspecific repolarization disturbance	1
	Normal	0
3) Age	≥ 65 year	2
	45-65 year	1
	< 45 year	0
4) Risk factors	≥ 3 risk factors or history of atherosclerotic disease	2

	1 or 2 risk factors	1
	No risk factors known	0
5) Troponin	>2x normal limit	2
	1-2x normal limit	1
	≤ normal limit	0

Low risk: the score of ≤3 AND troponin <99th percentile value

3. EDACS (16)

1) Age	score
18 – 45	+2
46 – 50	+4
51 – 55	+6
56 – 60	+8
61 – 65	+10
66 – 70	+12
71 – 75	+14
76 – 80	+16
81 – 85	+18
86 ≤	+20
2) Male sex	+6
3) Aged 18 – 50 years and either:	
a. known coronary artery disease	+4
b. ≥3 risk factors	
4) Symptom and signs	
Diaphoresis	+3
Radiates to arm or shoulder	+5
Pain occurred or worsened with inspiration	-4
Pain is reproduced by palpation	-6

Low risk: EDACS <16, AND no new ischemia on ECG, AND both 0 and 2 h troponin <99th percentile

4. T-MACS (17)

E) ECG ischemia

A) Worsening or crescendo angina

R) Right arm or shoulder pain

V) Vomiting

S) Sweating observed

H) Hypotension (systolic blood pressure < 100 mm Hg)

T) High-sensitivity troponin T concentration on arrival (ng/L)

Probability = $1 / (1 + e^{-(1.713E + 0.847A + 0.607R + 1.417V + 2.058S + 1.208H + 0.089T - 4.766)})$

Low risk: probability < 0.02

5. TRUST (35)

1) Modified Goldman risk score ≤ 1

- a. Typical new-onset chest pain at rest
- b. Pain the same as previous myocardial infarction
- c. Pain not relieved by glyceryl trinitrate spray within 15 min
- d. Pain lasting more than 60 min
- e. Pain occurring with increasing frequency
- f. Hypotension (systolic blood pressure < 100 mm Hg)
- g. Acute shortness of breath
- h. Pain within 6 weeks of a myocardial infarction or revascularization

2) Non-ischemic ECG

3) High-sensitivity troponin T concentration at presentation < 14 ng/L

Low risk: all parameters, 1), 2), and 3) are satisfied

6. GRACE (10)

1) Age	score
≤ 39	0
40 – 49	18

1		
2		
3		
4		
5		
6	50 – 59	36
7	60 – 69	55
8	70 – 79	73
9	80 – 89	91
10		
11	≥90	100
12		
13		
14	2) History of congestive heart failure	24
15		
16	3) History of myocardial infarction	12
17		
18	4) Resting heart rate (beats/min)	
19	≤49.9	0
20		
21	50 – 69.9	3
22		
23	70 – 89.9	9
24		
25	90 – 109.9	14
26		
27	110 – 149.9	23
28		
29	150 – 199.9	35
30		
31	≥200	43
32		
33	5) Systolic blood pressure (mm Hg)	
34	≤79.9	24
35		
36	80 – 99.9	22
37		
38	100 – 119.9	18
39		
40	120 – 139.9	14
41		
42	140 – 159.9	10
43		
44	160 – 199.9	4
45		
46	≥200	0
47		
48	6) ST-segment depression	11
49		
50	7) Initial serum creatinine (mg/dl)	
51	≤0.39	1
52		
53	0.4 – 0.79	3
54		
55	0.8 – 1.19	5
56		
57	1.2 – 1.59	7
58		
59	1.6 – 1.99	9
60		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2 – 3.99	15
≥4	20
8) Elevated cardiac enzymes	15
9) No in-hospital percutaneous coronary intervention	14
Low risk: the score of ≤140 AND both 0 and 2 h troponin <99 th percentile	

For peer review only

Section & Topic	No	Item	Reported on page #
TITLE OR ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)	3
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	3,4
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the index test	5-7
	4	Study objectives and hypotheses	7-8
METHODS			
<i>Study design</i>	5	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)	3
<i>Participants</i>	6	Eligibility criteria	9-10
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	10
	8	Where and when potentially eligible participants were identified (setting, location and dates)	9, 10
	9	Whether participants formed a consecutive, random or convenience series	3
<i>Test methods</i>	10a	Index test, in sufficient detail to allow replication	13-17, appendix
	10b	Reference standard, in sufficient detail to allow replication	18-19
	11	Rationale for choosing the reference standard (if alternatives exist)	19
	12a	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory	13-17
	12b	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	18-19
	13a	Whether clinical information and reference standard results were available to the performers/readers of the index test	18
	13b	Whether clinical information and index test results were available to the assessors of the reference standard	18
<i>Analysis</i>	14	Methods for estimating or comparing measures of diagnostic accuracy	20, 21
	15	How indeterminate index test or reference standard results were handled	18
	16	How missing data on the index test and reference standard were handled	19, 20
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	21
	18	Intended sample size and how it was determined	19, 20
RESULTS			
<i>Participants</i>	19	Flow of participants, using a diagram	
	20	Baseline demographic and clinical characteristics of participants	
	21a	Distribution of severity of disease in those with the target condition	
	21b	Distribution of alternative diagnoses in those without the target condition	
	22	Time interval and any clinical interventions between index test and reference standard	
<i>Test results</i>	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	
	25	Any adverse events from performing the index test or the reference standard	
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	
	27	Implications for practice, including the intended use and clinical role of the index test	
OTHER INFORMATION			
	28	Registration number and name of registry	11
	29	Where the full study protocol can be accessed	NA
	30	Sources of funding and other support; role of funders	23

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



STARD 2015

AIM

STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having a **target condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test**. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <http://www.equator-network.org/reporting-guidelines/stard>.

